5-HT3 receptor modulator, crystal form, preparation method and use
Patent Information
- Application Number
- CN202180034866.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-16
- Filing Date
- 2021-03-16
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2041-03-16
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application filed on March 16, 2020, in the U.S. Patent and Trademark Office and designated as Serial No. 62 / 990,228, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present invention relates to a 5-hydroxytryptamine 3-type (5-HT3) receptor modulator (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazole-6(7H)-one, its composition, free form and salt, and its use in treating diseases related to 5-HT3 receptors, for example, for treating symptoms caused by irritable bowel syndrome (IBS), chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV) and carcinoid syndrome. The present invention also relates to a method for preparing a salt of the 5-HT3 receptor modulator. Background Art
[0004] Irritable bowel syndrome (IBS) is a group of functional intestinal diseases characterized by persistent or intermittent attacks, and clinical manifestations include abdominal pain, bloating, changes in bowel habits and / or stool characteristics, and no gastrointestinal structural abnormalities. IBS is one of the functional intestinal diseases classified as Rome IV, and young and middle-aged people are the main patients. The age of onset is usually 20-50 years old, more common in women than in men, and has a tendency to cluster in families. IBS is often accompanied by other gastrointestinal disorders, such as functional dyspepsia.
[0005] Chemotherapy-induced nausea and vomiting remains the most distressing side effect for patients undergoing cancer treatment. Depending on the chemotherapy drug or regimen used, up to 90% of patients may experience some form of chemotherapy-induced nausea and vomiting (CINV). CINV symptoms can be severely debilitating and often cause patients to refuse further chemotherapy, with significant adverse consequences for cancer progression. In addition, CINV places a significant burden on the healthcare system, consuming healthcare staff time that could otherwise be caring for other patients or addressing other medical issues.
[0006] Postoperative nausea and vomiting (PONV) is nausea, vomiting or retching that occurs after surgery under anesthesia. It is an unpleasant complication that affects approximately 10% of people who undergo general anesthesia each year.
[0007] Carcinoid syndrome includes symptoms secondary to carcinoid tumors. The syndrome includes diarrhea, flushing, and vomiting, accompanied by excessive secretion of serotonin.
[0008] Studies have shown that 5-hydroxytryptamine (5-HT) is a key neurotransmitter in the gastrointestinal tract, and 5-hydroxytryptamine (5-HT3) receptors are key targets for the development of drugs for the treatment of irritable bowel syndrome, carcinoid syndrome, vomiting, etc. The applicant's early studies have shown that compounds having the structure of formula (I) can effectively regulate the activity of 5-HT3 receptors and have good application prospects in the preparation of drugs for the treatment of irritable bowel syndrome, carcinoid syndrome, vomiting, etc.
[0009]
[0010] Compound (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one (Formula (I)) can be used to treat inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, carcinoid syndrome, spastic dystonia, chronic pain, acute pain, sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, drug / toxin-induced cognitive dysfunction (e.g., alcohol, barbiturates, vitamin deficiency, recreational drugs, lead, arsenic, mercury-induced), disease-induced cognitive dysfunction (e.g., Alzheimer's disease (senile dementia), vascular dementia, Parkinson's disease , multiple sclerosis, AIDS, encephalitis, trauma, hepatorenal encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome and frontal and subcortical dementia), hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramolecular paralysis, chemical dependence and addiction (e.g., dependence or addiction to nicotine (and / or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's disease, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy including absence epilepsy, attention deficit hyperactivity disorder (ADHD), Tourette syndrome, especially nicotine dependence, addiction and withdrawal; including for smoking cessation treatment.
[0011] The compounds of formula (I) can also be used in pharmaceutical compositions in combination with antidepressants (e.g., tricyclic antidepressants or serotonin reuptake inhibiting antidepressants (SRIs)) to treat cognitive decline and depression associated with AD, PD, stroke, Huntington's disease or traumatic brain injury (TBI); in pharmaceutical compositions in combination with muscarinic agonists to stimulate central muscarinic and nicotinic receptors to treat ALS, cognitive dysfunction, age-related cognitive decline, AD, PD, stroke, Huntington's disease and TBI; in pharmaceutical compositions in combination with neurotrophic factors such as NGF to maximize cholinergic effects to treat, for example, ALS, cognitive dysfunction, age-related cognitive decline, AD, PD stroke, Huntington's disease and TBI; or in pharmaceutical compositions in combination with drugs that slow or prevent AD, such as cognitive enhancers, amyloid aggregation inhibitors, secretase inhibitors, tau kinase inhibitors, neuronal anti-inflammatory agents and estrogen-like therapies.
[0012] Compounds related to 5-hydroxytryptamine type 3 (5-HT3) receptor modulators include (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepina[5,4,3-cd]indazol-6(7H)-one or formula (I) See U.S. patent application serial number 13 / 941,304 filed on July 12, 2013, now U.S. Patent No. 8,710,047, which is a continuation of U.S. patent application serial number 13 / 372,967 filed on February 14, 2012, now U.S. Patent No. 8,501,729, which is a continuation of U.S. patent application serial number 12 / 473,940 filed on May 28, 2009, now U.S. Patent No. 8,124,600, which claims priority to U.S. provisional patent application serial number 61 / 057,014 filed on May 29, 2008. The aforementioned applications, which are co-owned with the present application and are incorporated herein by reference in their entirety, generally set forth pharmaceutically acceptable salts of the compounds described therein. Summary of the invention
[0013] The present invention relates to the free form and salt of (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one (formula (I)). The salt of the present invention includes one or more of adipate, benzenesulfonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-uronic acid salt, sorbate, phosphate, sulfate, L-tartrate, p-toluenesulfonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate.
[0014] In one embodiment, the present invention relates to the free form of (S)-7-(quinuclidin-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one. Figure 7 As shown, in powder X-ray diffraction measurement, the free base has a peak with a relative intensity of not less than 10% at a diffraction angle (2θ) shown in the following Table A-1.
[0015] Table A-1
[0016] 2θ diffraction angle (°) 11.3±0.2 14.6±0.2 17.2±0.2 18.6±0.2 21.8±0.2 23.6±0.2
[0017] In the diffraction angle (2θ) value, errors may sometimes occur, for example, attributable to the purity of crystals in the powder used for powder X-ray diffraction analysis, the particle size of the powder, errors caused by the measurement limit of the powder X-ray diffractometer, etc. In this specification, when a crystal is specified by using the diffraction angle (2θ), the diffraction angle is not limited to the measured value itself indicated as having a peak in the Example column. According to the United States Pharmacopeia USP <941> With regard to the recommendations outlined in the discussion of variability in the general section on X-ray powder diffraction, diffraction angles are generally considered to have a variability of ±0.2°. In addition to crystals of the free form, these also apply to crystals described below, such as the methanesulfonate, phosphate, hydrochloride, succinate, 1-hydroxy-2-naphthoate and L-pyroglutamate salts.
[0018] like Fig.10 As shown, the free form of formula (I) is characterized by its melting characteristic by DSC, showing an endotherm at 242°C.
[0019] In one embodiment, the present invention relates to the mesylate salt of formula (I). Fig.35 As shown, in the powder x-ray diffraction measurement, the mesylate salt has a peak with a relative intensity of not less than 10% at a 2θ diffraction angle, as shown in the following Table A-2.
[0020] Table A-2
[0021] 2θ diffraction angle (°) Relative strength (%) 10.2±0.2 57.7 11.3±0.2 13.5 12.9±0.2 19.5 17.0±0.2 19.8 18.7±0.2 14.5 19.6±0.2 100.0 23.9±0.2 25.3
[0022] like Fig.38 As shown, the mesylate salt is characterized by DSC which exhibits a single endothermic event at 302°C, which is attributed to the melting of the crystalline salt. In one embodiment, the mesylate salt is anhydrous.
[0023] In one embodiment, the present invention relates to phosphates of formula (I). Fig.48 As shown, in the powder X-ray diffraction measurement, the phosphate has a peak with a relative intensity of not less than 10% at a 2θ diffraction angle, as shown in the following Table A-3.
[0024] Table A-3
[0025] 2θ diffraction angle (°) Relative strength (%) 9.7±0.2 15.8 12.3±0.2 40.8 14.5±0.2 16.3 15.1±0.2 12.0 16.8±0.2 33.6 19.5±0.2 51.4 20.1±0.2 100.0 21.3±0.2 26.4 22.2±0.2 23.5 25.2±0.2 12.7 29.1±0.2 12.9
[0026] like Fig.51 As shown, the phosphate salt is characterized by DSC which exhibits a single endothermic event at 276° C., which is attributed to the melting of the crystalline salt. In one embodiment, the phosphate salt is anhydrous.
[0027] In one embodiment, the present invention relates to the hydrochloride salt of formula (I). Fig.76 As shown, in the powder X-ray diffraction measurement, the hydrochloride has a peak with a relative intensity of not less than 10% at a 2θ diffraction angle, as shown in the following Table A-4.
[0028] Table A-4
[0029] 2θ Diffraction angle 2θ(°) Relative strength (%) 17.7±0.2 100.0 21.5±0.2 17.8 22.3±0.2 43.9
[0030] like Fig.80 As shown, the hydrochloride salt is characterized by DSC which exhibits two endothermic events at 349° C. and 367° C., which are attributed to the melting of the crystalline salt. In one embodiment, the hydrochloride salt is anhydrous.
[0031] In another embodiment, the present invention relates to a succinate salt of formula (I). Fig.91 As shown, in the powder X-ray diffraction measurement, the succinate salt has a peak with a relative intensity of not less than 10% at a diffraction angle (2θ), as shown in the following Table A-5.
[0032]
[0033]
[0034] like Fig.94 As shown, the succinate salt was characterized by DSC, which showed a slight exotherm at the same temperature (273 °C) as the TGA step transition followed by melting at 220 °C.
[0035] In another embodiment, the present invention relates to 1-hydroxy-2-naphthoic acid salts of formula (I). Fig.86 As shown, in the powder X-ray diffraction measurement, 1-hydroxy-2-naphthoic acid salt has a peak with a relative intensity of not less than 10% at a diffraction angle (2θ), as shown in the following Table A-6.
[0036] Table A-6
[0037] 2θ diffraction angle (°) Relative strength (%) 6.5±0.2 100 10.7±0.2 26.5 14.2±0.2 14.9 14.6±0.2 24.4 17.4±0.2 36.2 19.2±0.2 55 20.2±0.2 13.3 20.5±0.2 39.8 21.4±0.2 49 23.2±0.2 20.4
[0038] like Figure 89(a) and 89(b)As shown, the 1-hydroxy-2-naphthoate salt is characterized by DSC, at the same temperature (200° C.), it shows a slight exotherm as a TGA step transition, followed by melting at 220° C. In one embodiment, the 1-hydroxy-2-naphthoate salt is anhydrous. In another embodiment, the 1-hydroxy-2-naphthoate salt is a hydrate.
[0039] In another embodiment, the present invention relates to L-pyroglutamate of formula (I). Fig.100 As shown, in the powder X-ray diffraction measurement, L-pyroglutamate has a peak with a relative intensity of not less than 10% at a diffraction angle (2θ), as shown in the following Table A-7.
[0040] Table A-7
[0041]
[0042]
[0043] As shown in Figure 103, the L-pyroglutamate salt is characterized in that it shows a single endothermic event at 241°C, which is attributed to the melting of the crystalline salt. In one embodiment, the L-pyroglutamate salt is anhydrous. In another embodiment, the L-pyroglutamate salt is a hydrate.
[0044] Another embodiment of the present invention relates to a pharmaceutical composition comprising at least one of the crystalline forms A, B, and C of (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one or its salt, and a pharmaceutically acceptable carrier or excipient for treating inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum, and Crohn's disease), irritable bowel syndrome, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, carcinoid syndrome, spastic dystonia, chronic pain, acute pain, sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, drug / toxin-induced cognitive dysfunction (e.g., alcohol, barbiturates, vitamin deficiency, recreational drugs, lead, arsenic, mercury-induced), disease cognitive impairment caused by drugs (e.g., Alzheimer's disease (senile dementia), vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, hepatorenal encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome and frontal and subcortical dementia), hypertension, bulimia, anorexia, obesity, cardiac arrhythmia, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramanalgia, chemical dependence and addiction (e.g., dependence or addiction to nicotine (and / or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's disease, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy including absence epilepsy, attention deficit hyperactivity disorder (ADHD) and Tourette syndrome. Another more preferred embodiment of the present invention is wherein the pharmaceutical composition is useful for treating nicotine dependence, addiction and withdrawal; most preferably for smoking cessation treatment.
[0045] The present invention also relates to a pharmaceutical composition for the use described in the preceding paragraphs, comprising any one of (S)-7-(quinuclidin-3-yl)-8,9-dihydro-2H-azepin[5,4,3-cd]indazol-6(7H)-one or its salts.
[0046] The present invention also relates to the use of the above-mentioned pharmaceutical composition in the preparation of a medicament for treating the following diseases, wherein the diseases include inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, chemotherapy-induced nausea and vomiting, postoperative nausea and vomiting, carcinoid syndrome, spastic dystonia, chronic pain, acute pain, sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorder, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, drug / toxin-induced cognitive dysfunction (e.g., alcohol, barbiturates, vitamin deficiency, recreational drugs, lead, arsenic, mercury-induced), disease-induced cognitive dysfunction (e.g., Alzheimer's disease (senile dementia), vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, hepatorenal encephalopathy, hypothyroidism, Pick's disease, Korsakoff's syndrome and frontal lobe and subcortical dementia), hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramandrhoea, chemical dependence and addiction (e.g., dependence or addiction to nicotine (and / or tobacco products), alcohol, benzodiazepines, barbiturates, opioids, or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's disease, tardive dyskinesia, hyperkinesia, reading disorder Dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy including childhood absence epilepsy, attention deficit hyperactivity disorder (ADHD) and Tourette syndrome, the method comprising administering to an individual in need of treatment a therapeutically effective amount of a salt of formula (I) or (S)-7-(quinuclidin-3-yl)-8,9-dihydro-2H-azepinazole[5,4,3-cd]indazol-6(7H)-one in Form A, Form B, Form C or other forms.
[0047] The present invention also relates to a method for preparing the crystalline form A, form B or form C of a salt of (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one, which comprises the steps of (i) contacting (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one with 1 and 2 equivalents of an acid in a suitable solvent; and (ii) collecting the formed crystals.
[0048] A preferred embodiment of the present invention relates to the above method, wherein about 1.1 equivalents of acid are used and the acid is added to the solution containing the free base. A preferred mode of carrying out the method is wherein the contacting step is allowed to proceed for less than 2 hours. A more preferred embodiment of the present invention relates to the above method, wherein the contacting step (i.e., step "(i)" above) can be carried out at 30 to 120°C.
[0049] Another preferred embodiment of the present invention relates to the above method, wherein the suitable solvent is selected from (C1-C6) alkyl alcohols, (C1-C6) alkyl ketones, (C1-C6) alkyl ethers, acetonitrile and (C1-C6) alkyl esters (e.g. ethyl acetate, isopropyl acetate, etc.). More preferably, the suitable solvent is ethanol.
[0050] Further, another embodiment relates to a polymorph of a compound having a structure represented by formula (I). Optionally, the polymorph is characterized by at least one of the following powder x-ray diffraction pattern peak angles expressed as 2θ (°) (± 0.20°), measured using copper Kα radiation, wherein the 2θ is selected from 11.3, 14.6, 17.2, 18.57, 21.8 and 23.6.
[0051] Another embodiment also relates to a method for preparing a polymorph of a compound having a structure shown in formula (I). The method may include the following steps: for example, in the presence of one or more solvents selected from diisopropyl ether, ethanol or isopropanol, placing the compound at a temperature such as room temperature.
[0052] Optionally, in any embodiment, the vehicle may comprise isopropanol.
[0053] Another embodiment also relates to a pharmaceutical preparation. The pharmaceutical composition may include a polymorph of the compound having the structure shown in formula (I) and a pharmaceutically acceptable excipient.
[0054] Another embodiment relates to a method for treating a disease. The method may include the following step: administering a therapeutically effective amount of a polymorph of a compound of formula (I) to an individual in need of such treatment.
[0055] Yet another embodiment is directed to a polymorph of a compound having the structure shown in Formula (I) for use as a medicament.
[0056] The free forms and salts of (S)-7-(quinuclidin-3-yl)-8,9-dihydro-2H-azepinazo[5,4,3-cd]indazol-6(7H)-one, such as adipate, benzenesulfonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-saccharate, sorbate, phosphate, sulfate, L-tartrate, p-toluenesulfonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamic acid, are relatively inert to common excipients, making them very suitable for use in pharmaceutical formulations.
[0057] The object of the present invention is to provide a relatively stable and soluble free form and salt of a 5-HT3 receptor modulator (Formula (I)), as well as a crystalline form thereof, and the object of the present invention is also to provide the use of the above-mentioned salt or crystal in the preparation of a drug for preventing and / or treating 5-HT3 receptor-related diseases such as irritable bowel syndrome, carcinoid syndrome, vomiting, etc.
[0058] The present invention provides free forms and salts of formula (I):
[0059]
[0060] As used above, and throughout the specification of the present invention, unless otherwise indicated, the following terms shall be understood to have the following meanings.
[0061] The term "alkyl" means an aliphatic or cyclic hydrocarbon group containing about 1 to 6 carbon atoms in the chain, which may be straight or branched. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear alkyl chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl and 3-pentyl.
[0062] The term "compound" and equivalent expressions refer to compounds comprising the general formula (I) as described above, and where the context permits, the expression includes prodrugs, pharmaceutically acceptable salts, oxides and solvates such as hydrates. Similarly, reference to intermediates, whether or not they are claimed themselves, where the context permits, is intended to include their salts and solvates. For the sake of clarity, special cases where the context permits are sometimes indicated in the text, but these cases are purely illustrative and, where the context permits, are not intended to exclude other cases.
[0063] The term "treatment method" means improving or alleviating the symptoms and / or effects associated with a condition as described herein. As used herein, reference to "treatment" of a patient is intended to include prevention.
[0064] The compounds described herein may contain one or more asymmetric centers, and thus may give rise to enantiomers, diastereomers, and other stereoisomeric forms. In terms of absolute stereochemistry, each chiral center may be defined as either (R)- or (S)-. The present invention is intended to include all such possible isomers, and mixtures thereof, including racemic and optically pure forms. Optically active (R)- and (S)-, (-)- and (+)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise indicated, it is contemplated that the compounds include E and Z geometric isomers. Likewise, all tautomers are contemplated to be included.
[0065] As used herein, and as will be understood by those skilled in the art, reference to a "compound" is intended to include salts, solvates, oxides, and inclusion compounds of the compound and any stereoisomeric form, or mixtures of any proportion of any of the said forms of the compound. Thus, according to some embodiments of the present invention, providing the compounds described herein in the form of a salt is included in the context of pharmaceutical compositions, methods of treatment, and the compound itself.
[0066] The term "solvate" refers to a solid-state compound of formula (I) in which suitable solvent molecules are incorporated into the crystal lattice. A solvent suitable for therapeutic administration is physiologically tolerable at the dose administered. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is referred to as a hydrate. Typically, a solvate is formed by dissolving the compound in a suitable solvent and separating the solvate by cooling or using an antisolvent. Solvates are typically dried or azeotroped at ambient conditions.
[0067] Inclusion compounds are described in Remington, The Science and Practice of Pharmacy, 19th Edition, 1:176-177 (1995), which is incorporated herein by reference in its entirety. The most commonly used inclusion compounds are those utilizing cyclodextrins, and all cyclodextrin complexes, both natural and synthetic, are specifically included in the claims.
[0068] The term "salt" refers to a salt prepared from a pharmaceutically acceptable non-toxic acid or base (including inorganic acids and bases and organic acids and bases). Since the compound of formula (I) contains basic nitrogen, the salt can be prepared from a pharmaceutically acceptable non-toxic acid (including inorganic acids and organic acids). For the compounds of the present invention, suitable pharmaceutically acceptable acid addition salts include acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, vinylsulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, etc. When the compound contains an acidic side chain, suitable pharmaceutically acceptable base addition salts for the compounds of the present invention include metal salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or organic salts made from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
[0069] The configuration of any carbon-carbon double bond appearing herein is chosen for convenience only and is not intended to specify a particular configuration; thus, any carbon-carbon double bond described herein as E may be Z, E, or a mixture of the two in any ratio.
[0070] The term "therapeutically effective amount" is meant to describe an amount of a compound of the invention that is effective in modulating 5-HT3 activity and thereby producing the desired therapeutic effect. The amount generally varies depending on a number of factors, and variations in the amount are well within the purview of the skilled artisan as determined and understood by the specification provided herein. The factors include, but are not limited to, the particular individual, and his or her age, weight, height, general physical condition and medical history, the particular compound used, as well as the formulation carrier and the route of administration selected; and the nature and severity of the condition being treated.
[0071] The term "pharmaceutical composition" means a composition comprising a compound of formula (I) and at least one component, which includes a pharmaceutically acceptable carrier, diluent, adjuvant, excipient or solvent, such as a preservative, filler, disintegrant, wetting agent, emulsifier, suspending agent, sweetener, flavoring agent, fragrance, antibacterial agent, antifungal agent, lubricant and dispersant, depending on the mode of administration and the nature of the dosage form.
[0072] As used herein, the term "pharmaceutically acceptable carrier" is used to mean any carrier, diluent, adjuvant, excipient or solvent described herein. Examples of suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitol esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth gum or mixtures of the substances. Preventive action on microorganisms can be ensured by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, etc. The use of substances that delay absorption, such as aluminum monostearate and gelatin, can prolong the absorption of injectable drug forms. Examples of suitable carriers, diluents, solvents or solvents include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (e.g., olive oil) and injectable organic esters (e.g., ethyl oleate). Examples of excipients include lactose, sodium citrate, calcium carbonate and dicalcium phosphate. Examples of disintegrants include starch, alginic acid and certain complex silicates. Examples of lubricants include magnesium stearate, sodium lauryl sulfate, talc, and high molecular weight polyethylene glycols.
[0073] The term "pharmaceutically acceptable" means that it is, within the scope of sound medical judgment, suitable for use in contact with cells of humans and lower animals without excessive toxicity, irritation, allergic response, etc., and is commensurate with a reasonable benefit / risk ratio.
[0074] One embodiment of the present invention relates to any one of the compounds of formula (I) described herein in a pharmaceutically acceptable salt or non-salt form.
[0075] The individual enantiomers, any mixtures of enantiomers (including racemic mixtures), or diastereomers (resolved and as any mixture) of the compounds of the present invention are also included within the scope of the present invention.
[0076] Also included within the scope of the present disclosure are active metabolites of the compounds of the present invention.
[0077] The compounds of the invention described herein are useful as 5-HT3 receptor modulators. Upon review, it is found that compounds that are not currently excluded from the claims are not patented by the inventors in this application. In this case, the exclusion of species and genera in the applicant's claims should be considered an artifact of patent prosecution and does not reflect the inventor's concept or description of his invention. In terms of compounds, the invention is all compounds of formula (I) other than publicly owned compounds.
[0078] Although it is possible to administer the compound of formula (I) as a raw material, it is usually best to use it as part of a pharmaceutical composition. Therefore, another aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier. The carrier must be "acceptable", i.e., compatible with the other ingredients of the formulation and harmless to its recipient. In addition, when a compound or a pharmaceutically acceptable salt thereof is mentioned in an independent claim, it should be understood that a claim that relies on an independent claim that mentions the compound also includes a pharmaceutically acceptable salt of the compound, even if these salts are not explicitly mentioned.
[0079] In one embodiment of the present invention, the pharmaceutical composition further comprises one or more other therapeutic ingredients, such as other compounds effective in treating IBS, CINV or PONV, which are well known to those skilled in the art. The other therapeutic drugs are described below.
[0080] Another aspect of the present invention relates to a method for treating a disease or condition that is sensitive to treatment with a 5-HT3 receptor modulator. The method comprises selecting a patient suffering from a disease or condition that is sensitive to treatment with a 5-HT3 receptor modulator and administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0081] According to the present invention, diseases or conditions susceptible to treatment with 5-HT3 receptor modulators include, but are not limited to, general anxiety disorder, social phobia, vertigo, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, bulimia nervosa, drug withdrawal effects, alcohol dependence, pain (including visceral pain), sleep-related central apnea, chronic fatigue syndrome, Parkinson's disease psychosis, schizophrenia, cognitive decline and schizophrenia deficits, Parkinson's disease, Huntington's disease, pre-senile dementia, Alzheimer's disease, psychological disorders, obesity, substance abuse disorders, dementia associated with neurodegenerative diseases, cognitive deficits, fibromyalgia syndrome (see U.S. Patent Application Publication No. 2004 / 0204467, which is incorporated herein by reference in its entirety), rosacea (see PCT Publication No. WO 2007 / 138233, which is incorporated herein by reference in its entirety), serotonin-mediated cardiovascular disease, chemotherapy-induced nausea and vomiting (CINV), postoperative induced nausea and vomiting (PONV), radiation-induced nausea and vomiting (RINV), gastrointestinal patients (see esophageal, gastric and large and small intestine patients) including irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD) (see European Patent No. EP0430190, U.S. Patent No. 6,967,207 and U.S. Patent No. 5,352,685, which are incorporated herein by reference in their entirety), bronchial asthma, pruritus, migraine (see Costall et al., Current Drug Targets—CNS & Neurological Disorders, 3:27-37 (2004) and Israili, Current Med. Chem.—CNS Agents, 1: 171-199 (2001), which is incorporated herein by reference in its entirety), and epilepsy (see PCT Publication No. WO2007 / 010275, which is incorporated herein by reference in its entirety).
[0082] In another embodiment of the present invention, the above method further comprises administering a therapeutically effective amount of one or more schizophrenia or Parkinson's disease adjuvants. Suitable schizophrenia adjuvants include, but are not limited to, sodium valproate and levomeprazole. Suitable Parkinson's disease adjuvants include, but are not limited to, transdermal rotigotine, rotigotine and / or rasagiline as levodopa adjuvants, levodopa, carbidopa, dopamine agonists (bromocriptine, pramipexole or ropinirole), COMT inhibitors (entacapone or tolcapone), MAO-B inhibitors (rasagiline or selegiline), amantadine, anticholinergics (benztropine or trihexyphenidyl) and safinamide. The composition may additionally include alprazolam, haloperidol, chlorpromazine, risperidone, paliperidone, olanzapine, ziprasidone, quetiapine, clozapine, lithium carbonate, diazepam, carbamazepine, selective serotonin reuptake inhibitors (SSRI's) ( or ) or tricyclic antidepressants such as
[0083] Another aspect of the present invention relates to a method for treating irritable bowel syndrome (IBS). The method comprises selecting an IBS patient and administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0084] In another embodiment of the present invention, the above method further comprises administering a therapeutically effective amount of other 5-hydroxytryptamine 5-HT3 receptor modulators and / or 5-hydroxytryptamine 5-HT4 receptor modulators, some of which are described below. Suitable other 5-hydroxytryptamine 5-HT3 receptor modulators and / or 5-hydroxytryptamine 5-HT4 receptor modulators include, but are not limited to, alosetron Renzapride, Cilansetron, Tegaserod Prucalopride, ondansetron; somatostatin analogs such as octreotide; muscarinic receptor antagonists such as darifenacin and zalifenacin; laxatives such as methylcellulose Plantago Malt broth extract, polyacrylic acid resins (e.g., hydrophilic forms such as polycarbophil and calcium polycarbophil), psyllium seeds, calcium thiosuccinate, potassium thiosuccinate, sodium thiosuccinate, mineral oil, magnesium citrate, magnesium hydroxide, magnesium sulfate, disodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate, glycerin, anthraquinones or anthracene laxatives (e.g., aloe, cascara bark, danthron, senna, aloesin, cascara anthranol, cascara and rhubarb), diphenylmethanes (e.g., bisacodyl and phenolphthalein) and castor oil, etc.; antispasmodics, such as the anticholinergic drug bicycline hydrochloride Hydroxycytosine sulfate etc.; Antidepressants, such as imipramine Amitriptyline Antidiarrheal drugs, such as diphenoxylate hydrochloride + atropine sulfate Loperamide Natural or synthetic opioids (e.g., difenoxin, diphenoxylate, compound camphor tincture, opium tincture and loperamide), anticholinergics (e.g., belladonna alkaloids-atropine, scopolamine and scopolamine), acetyltannic acid, tannic acid protein, aminosulphonamide, aluminum salicylate, catechins, ritamine, mebiquinol, trillium and ursagin, etc.; prokinetic agents, peripheral opioid narcotic antagonists such as fedotozine, trimebutine, etc. Suitable prokinetic agents include but are not limited to cisapride monohydrate Metoclopramide, morphine, etc.
[0085] Another aspect of the present invention relates to a method for treating emesis, which comprises selecting a patient suffering from emesis and administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0086] In another embodiment of the present invention, the above method further comprises administering a therapeutically effective amount of one or more other antiemetic compounds. Suitable antiemetic compounds include, but are not limited to, alosetron, alprazolam, aprepitant, dexamethasone, dimenhydrinate, diphenhydramine, dolasetron, tetrahydrocannabinol, enopyrone, dronabinol, droperidol, granisetron, haloperidol, lorazepam, metoclopramide, midazolam, olanzapine, ondansetron, palonosetron, prochlorperazine, promethazine and tropisetron.
[0087] Another aspect of the present invention also relates to a method for treating a CNS disease or condition. The method comprises selecting a patient suffering from a CNS disease or condition and administering to the patient an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Suitable CNS diseases or conditions include, but are not limited to, schizophrenia and Parkinson's disease. The beneficial effects of 5-HT3 modulators have been reported in clinical studies of Parkinson's disease (Zoldan J et al., Advances in Neurology, 69: 541-544 (1996), which is incorporated herein by reference in its entirety) and schizophrenia (Zhang-Jin et al., Schizophrenia Research, 88: 102-110 (2006); Alder et al., Am. J. Psychiatry, 162: 386-388 (2005), which is incorporated herein by reference in its entirety). When alosetron is used to treat IBS patients, the human brain response is altered (Mayer et al., Aliment Pharmacol. Ther., 16:1357-1366 (2002), which is incorporated herein by reference in its entirety.) 5-HT3 modulators can be used as adjuncts or in combination with other drugs.
[0088] It should be understood that, for the sake of clarity, certain features of the present invention (which are described in the context of separate embodiments) may also be provided in combination in a single embodiment. Conversely, for the sake of brevity, various features of the present invention (described in the context of a single embodiment) may also be provided separately or in any suitable sub-combination.
[0089] Another aspect of the present invention relates to a method for preparing a salt of formula (I). The method comprises (i) contacting formula (I) or (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepino[5,4,3-cd]indazol-6(7H)-one with about 1 to about 2 equivalents of an acid in a suitable solvent; and (ii) collecting the crystals formed. Another aspect of the present invention also relates to polymorphs of various salts. The salt of formula (I) may exist in a variety of polymorphs: anhydrous form, solvate form or some other non-solvated form.
[0090] In some embodiments, one polymorph may be converted to another polymorph under appropriate conditions.
[0091] The salt can be further purified by crystallization or recrystallization. The crystallization or recrystallization method can be standing or stirring. More specifically, the crystallization method can preferably be stirring. The temperature of the crystallization method can be -10 to 60°C, preferably room temperature.
[0092] Differential Scanning Calorimetry
[0093] The solid-state thermal behavior of the crystalline forms A, B, C and other forms of the salt of (S)-7-(quinuclidine-3-yl)-8,9-dihydro-2H-azepina[5,4,3-cd]indazol-6(7H)-one was studied by differential scanning calorimetry. e DSC spectra were obtained on a flared aluminum pan. Typically, 1-10 mg of sample was prepared in a corrugated aluminum pan with a small pinhole. Measurements were made in the range of 30-400°C at a heating rate of 10°C per minute.
[0094] However, those skilled in the art should note that in DSC measurement, the actual measured onset temperature and peak temperature vary to a certain extent, depending on the heating rate, crystal shape and purity, and some measurement parameters.
[0095] Powder X-ray diffraction pattern
[0096] The powder x-ray diffraction patterns of Form A, Form B, Form C or other forms of salts were collected using a PANalytical CubiX-Pro XRD equipped with copper Kα radiation, divergence slit (automatic 1.0 mm) and a Kevex solid-state detector (CuKV, 45 kV). Data were collected at 2θ (2θ) of 3.0 to 40.0°, using a 0.03° step length and a 10 second step time.
[0097] The x-ray powder diffraction pattern of the salt was obtained with a copper anode. The 2θ range was 3.0 to 45.0°, the step size was 0.03°, the step time was 1.00 s, the smoothing width was 0.300°, and the threshold was 1.0.
[0098] In the measured powder X-ray diffraction analysis of Form A, diffraction peaks at diffraction angles (2θ) are shown in Table I. However, the relative intensity may vary depending on the crystal size and morphology.
[0099] The salts of the present invention (hereinafter referred to as "active salts") can be administered orally, transdermally (e.g., by using a patch), intranasally, sublingually, rectally, parenterally or topically. Transdermal and oral administration are preferred. Optimally, these salts are administered at a dose of about 0.01 mg / day to a maximum of 1500 mg / day, preferably about 0.1 mg / day to about 300 mg / day in a single dose or divided dose, although changes will inevitably occur depending on the weight and condition of the subject being treated and the specific route of administration selected. However, the most ideal dosage level is about 0.001 mg to 10 mg / kg body weight per day. However, changes may occur depending on the weight and condition of the subject being treated, their individual response to the drug, the type of pharmaceutical preparation selected, and the time and interval of administration. In some cases, dosage levels below the lower limit of the above range may be completely sufficient, while in other cases, larger doses may still be used without causing any harmful side effects, provided that the large dose is first divided into several small doses and administered throughout the day.
[0100] Active salts can be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the aforementioned routes. More specifically, active salts can be administered in a variety of different dosage forms, for example, they can be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, transdermal patches, lozenges, lozenges, hard candies, powders, sprays, emulsions, ointments, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injection solutions, elixirs, syrups, etc. The carriers include solid diluents or fillers, sterile aqueous solvents, and various nontoxic organic solvents. In addition, oral pharmaceutical compositions can be appropriately sweetened and / or flavored. Typically, the active compound is present in the dosage form at a concentration level of about 5.0% by weight to about 70% by weight.
[0101] When administered orally, tablets containing various excipients can be used, such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine, various disintegrants such as starch (preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, and granulated binders such as polyvinyl pyrrolidone, sucrose, gelatin and gum arabic. In addition, lubricants such as magnesium stearate, sodium lauryl sulfate and talc can be used for tableting. Similar types of solid compositions can also be used as fillers in gelatin capsules; in this regard, preferred materials also include lactose or lactose, and high molecular weight polyethylene glycols. When aqueous suspensions and / or elixirs are required for oral administration, the active ingredient can be combined with various sweeteners or flavoring agents, colorants and emulsifiers and / or suspending agents, as well as diluents such as water, ethanol, propylene glycol, glycerol and various combinations thereof, if necessary.
[0102] For parenteral administration, sesame or peanut oil or aqueous propylene glycol solutions of the active salts may be used. If necessary, the aqueous solution should be appropriately buffered (preferably pH greater than 8), and the liquid diluent is first isotonic. The aqueous solution is suitable for intravenous injection. Oily solutions are suitable for intra-articular, intramuscular and subcutaneous injections. The preparation of all the solutions under sterile conditions is easily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
[0103] It is also possible to administer the active salts topically, and this may be accomplished by means of creams, patches, jellies, gels, pastes, ointments, etc., consistent with standard pharmaceutical practice.
[0104] The present invention discloses experiments conducted by a series of salt formation studies using a variety of solvents and counterion combinations. The project was conducted in a multi-stage approach to detect crystalline salts of formula (I), including initial screening at the 4 mg level using a variety of conditions and subsequent scale-up experiments. Formula (I) was confirmed to form crystalline and / or semi-crystalline salts with the following counterions: adipic acid, benzenesulfonic acid, hydrobromic acid, fumaric acid, benzoic acid, methanesulfonic acid, L-malic acid, sorbic acid, phosphoric acid, sulfuric acid, L-tartaric acid, p-toluenesulfonic acid, citric acid, hydrochloric acid, ethanesulfonic acid, 1-hydroxy-2-naphthoic acid, succinic acid, glutaric acid and 2-pyrrolidine-5-carboxylic acid. After preliminary characterization, 6 salt candidates were identified for further evaluation of physical properties, including: methanesulfonic acid, phosphoric acid, hydrochloric acid, succinic acid, 1-hydroxy-2-naphthoic acid and 2-pyrrolidine-5-carboxylic acid. These selections were based on the following considerations: improved solubility over the free form, crystallinity, thermal stability (Mp) and safety. Each of the six salts was further characterized, including stability evaluation under slurry conditions and high temperature / high humidity. Based on the analytical results, the mono-HCl salt of formula (I) was recommended as the final salt form of formula (I). The hydrochloride salt exhibited the most ideal physical properties of the salts studied, including high solubility in water and form stability under high temperature, high humidity and slurry conditions. Phosphates and glutamates were also observed to be useful salts. The phosphate salt was found to be slightly hygroscopic and showed improved water solubility compared to the free form. The glutamate salt also showed good solubility, however, it deliquesced under conditions of relative humidity (RH) above 80%, which may lead to the formation of a stable monohydrate. The methanesulfonate salt is not recommended due to the additional testing requirements required for the genotoxic impurities separated from the alcohol solvent. The succinate and naphthoate salts are not recommended because these salts show conversion to hydrate forms with limited RH stability. This article outlines the experimental conditions used to produce all materials, the evaluation of each stage of salt testing, and the characterization of the salt types.
[0105] 41 conditions that provided solids were scaled up to 70 mg to provide additional material for confirmation of salt formation and further characterization, the solids either showing birefringence, unique Raman spectra compared to the free form or increased water solubility. Crystalline or semi-crystalline solids recovered from these experiments were analyzed by XRPD, Raman, optical microscopy, DSC, TGA, ICP / OES, 1H-NMR and weight solubility in water. Among the counterions studied, crystalline and / or semi-crystalline salts of formula (I) with adipic acid, benzenesulfonic acid, hydrobromic acid, fumaric acid, benzoic acid, methanesulfonic acid, L-malic acid, sorbic acid, phosphoric acid, sulfuric acid, L-tartaric acid, p-toluenesulfonic acid, citric acid, hydrochloric acid, ethanesulfonic acid, 1-hydroxy-2-naphthoic acid, succinic acid, glutaric acid and L-pyroglutamic acid (2-pyrrolidine-5-carboxylic acid) were observed. Six salt forms were determined for further evaluation of physical properties, including: methanesulfonic acid, phosphoric acid, hydrochloric acid, succinic acid, 1-hydroxy-2-naphthoic acid, and 2-pyrrolidine-5-carboxylic acid (Table 7). These salts were selected based on the following features, including: improved water solubility, crystallinity, melting point (MP) predicted thermal stability, and safety compared to the free form. Among these counterions, succinic acid, L-pyroglutamic acid, and hydrochloric acid were scaled up to 200 mg to produce additional materials for further characterization. The stability of each salt was evaluated by room temperature slurrying in organic solvents and water, storage at high temperature (60°C), and exposure to high relative humidity by weight hygroscopicity. The solubility of each salt was determined under ambient conditions based on the water slurry. Except for naphthoate, it was observed that each of the six salts was stable after slurrying experiments and exposure to high temperatures. It was confirmed that naphthoate was the salt with the lowest solubility, showing water solubility comparable to the free form. According to the gravimetric hygroscopic experiments, succinate, glutamate and naphthoate showed a tendency to form hydrates. Among these salts, only glutamate showed hydrate potential and was stable over a wide range of humidity. Methanesulfonic acid was observed to have moderate hygroscopicity, while phosphate and hydrochloride had the least affinity for water adsorption. Overall, many viable crystalline salt candidates have been identified; however, it was concluded that the hydrochloride salt has the most ideal physical properties, including: better stability than the free form of formula (I), low hygroscopicity and significantly improved solubility (Table 7).
[0106] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0107] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0108] Figure 1 is the DSC thermogram of monoglutamate salt Form A-batch HALG-26(40) formed from THF.
[0109] Figure 2 is the moisture absorption curve of monoglutamate salt form A-batch HAL-G-29(2) formed from THF.
[0110] Figure 3 The Raman spectra are: glutamate salt form A-batch HAL-G-26 (40), glutamate salt form B-batch HAL-G-32 (11), formula (I) free form form A-batch LMA-U-133 (2). Compared with the free form, the specific Raman peak is ↓, and in each corresponding salt form ↓, the red curve is the free form.
[0111] Figure 4 It is the TGA chart of monoglutamate crystal form B-batch HAL-G-32 (11).
[0112] Figure 5 It is the DSC thermogram of monoglutamate crystal form B-batch HAL-G-32 (11).
[0113] Figure 6 is the HPLC calibration curve of formula (I) used to determine water solubility.
[0114] Figure 7 The following are stacked images of XRPD patterns: (a) free base Form A - batch LMA-U-133 (2); (b), Form A - batch LMA-U-133 after hygroscopicity analysis (2) AD; (c) Form A - batch HAL-G-31 (9) after slurrying in water at room temperature overnight; (d) Form B, IPA solvate of formula (I) - batch HAL-G-32 (7); Figure 8 This is the Raman spectra of the free form of ALB137391: Form A - Batch LMA-U-133 (2), Form B, IPA solvate of formula (I) - Batch HAL-G-32 (7). ↓ indicates a unique Raman peak, red curve = free form;
[0115] Fig. 9 yes 1 Stacked plots of H-NMR spectra: (a) Free base Form A - Batch LMA-U-133 (2), observed resonance of unknown impurity *; (b) Form B, IPA solvate of formula (I) - Batch HAL-G-32 (7);
[0116] Fig.10 is the DSC thermogram of free base crystalline form A-batch LMA-U-133(2);
[0117] Fig.11 is the moisture absorption curve of free base crystalline form A-batch LMA-U-133(2);
[0118] Fig.12 is an optical micrograph of free base crystalline form A-batch LMA-U-133(2);
[0119] Fig.13 is the TGA chart of Form B, mono-IPA solvate of formula (I) - batch HAL-G-32 (7);
[0120] Fig.14 is the DSC graph of Form B, mono-IPA solvate of formula (I) - batch HAL-G-32 (7);
[0121] Fig.15 It is a stacked diagram of XRPD patterns: (a) adipate salt form A formed from EtOH - batch HAL-G-26 (1); (b) adipate salt form A formed from IPA - batch HAL-G-26 (2); (c) formula (I) free form - batch LMA-U-133 (2);
[0122] Fig.16 is an optical micrograph of adipate salt formed from IPA - batch HAL-G-26 (2);
[0123] Fig.17 Adipate salt form A-batch HAL-G-26(2) formed from IPA 1 H-NMR spectrum;
[0124] Fig.18 is the DSC graph of adipate salt crystalline form A-batch HAL-G-26(2) formed from IPA;
[0125] Fig.19 The stacked diagram of XRPD patterns: (a) benzenesulfonate salt form A formed from THF - batch HAL-G-26 (3); (b) benzenesulfonate salt form B formed from IPA - batch HAL-G-26 (4); (c) free form of formula (I) - batch LMA-U-133 (2);
[0126] Fig. 20 It is stacked 1 H-NMR spectra: (a) benzenesulfonate salt form A formed from THF – batch HAL-G-26 (3); (b) benzenesulfonate salt form B formed from IPA – batch HAL-G-26 (4);
[0127] Fig.21is the DSC spectrum of benzenesulfonate salt form A-batch HAL-G-26(3) formed in THF;
[0128] Fig. 22 is an optical micrograph of benzenesulfonate salt Form B – Batch HAL-G-26(4) formed from IPA;
[0129] Fig.23 is the DSC spectrum of benzenesulfonate salt form B-batch HAL-G-26(4) formed from IPA;
[0130] Fig.24 The following are stacked images of XRPD patterns: (a) hydrobromide salt form A formed from THF - batch HAL-G-26 (5); (b) hydrobromide salt form A formed from IPA - batch HAL-G-26 (6); (c) free form of formula (I) - batch LMA-U-133 (2);
[0131] Fig.25 is an optical micrograph of the hydrobromide salt Form A-Batch HAL-G-26(6) formed from IPA;
[0132] Fig.26 is the DSC spectrum of the hydrobromide salt form A-batch HAL-G-26(6) formed from IPA;
[0133] Fig. 27 The following are stacked images of XRPD patterns: (a) Form A fumarate salt formed from THF - Batch HAL-G-26 (9); (b) Form A fumarate salt formed from IPA - Batch HAL-G-26 (10); (c) free form of formula (I) - Batch LMA-U-133 (2);
[0134] Fig.28 is an optical micrograph of the fumarate salt Form A-Batch HAL-G-26 (9) formed from THF;
[0135] Fig.29 Fumarate Form A – Batch HAL-G-26 (9) was formed from THF 1 H-NMR spectrum;
[0136] Fig.30 is the DSC spectrum of the fumarate salt Form A-batch HAL-G-26(9) formed from THF;
[0137] Fig.31The following are stacked images of XRPD patterns: (a) Benzoate salt Form A formed from THF - Batch HAL-G-26 (11); (b) Benzoate salt Form A formed from IPA - Batch HAL-G-26 (12); (c) Formula (I) free form - Batch LMA-U-133 (2);
[0138] Fig.32 is an optical micrograph of Form A of the benzoate salt formed from IPA – batch HAL-G-26 (12);
[0139] Fig.33 Benzoate Form A – Batch HAL-G-26 (12) formed from IPA 1 H-NMR spectrum;
[0140] FIG34( a ) is a TGA spectrum of Form A of the benzoate salt formed from IPA, batch HAL-G-26 (12); FIG34( b ) is a DSC spectrum of Form A of the benzoate salt formed from IPA, batch HAL-G-26 (12); Fig.35 The following are stacked images of XRPD patterns: (a) mesylate salt form A formed from THF – batch HAL-G-26 (13); (b) mesylate salt form A formed from IPA – batch HAL-G-26 (14); (c) mesylate salt form A after gravimetric moisture absorption – batch HAL-G-26 (13) AD; (d) mesylate salt form A after 7 days of equilibrium in THF – batch HAL-G-32 (1); (e) mesylate salt form A after 7 days of exposure at 60°C – batch HAL-G-30 (2); (f) free form of formula (I) – batch LMA-U-133 (2);
[0141] Fig.36 is an optical micrograph of the mesylate salt Form A-Batch HAL-G-26 (13) formed from THF;
[0142] Fig.37 Form A of the mesylate salt of batch HAL-G-26 (13) was formed from THF 1 H-NMR spectrum;
[0143] Fig.38 is the DSC spectrum of mesylate salt Form A-batch HAL-G-26 (13) formed from THF;
[0144] Fig.39 is the moisture absorption curve of mesylate salt Form A-batch HAL-G-26(13) formed from THF;
[0145] Fig.40The following are stacked images of XRPD patterns: (a) malate salt Form A formed from THF - batch HAL-G-26 (15); (b) malate salt Form A formed from IPA - batch HAL-G-26 (16); (c) free form of formula (I) - batch LMA-U-133 (2);
[0146] Fig.41 is an optical micrograph of malate Form A formed from IPA – batch HAL-G-26 (16);
[0147] Fig.42 Malate Form A – Batch HAL-G-26 (16) formed from IPA 1 H-NMR spectrum;
[0148] Fig.43 is the TGA spectrum of malate Form A-batch HAL-G-26 (16) formed from IPA;
[0149] Fig.44 is the DSC spectrum of malate Form A-batch HAL-G-26(16) formed from IPA; Fig.45 The XRPD patterns are stacked: (a) Sorbate Form A formed from IPA – Batch HAL-G-26 (20); (b) LB137391 free form – Batch LMA-U-133 (2);
[0150] Fig.46 Sorbate Form A from IPA – Batch HAL-G-26(20) 1 H-NMR spectrum;
[0151] Fig.47 is the DSC spectrum of sorbate salt form A-batch HAL-G-26(20) formed from IPA; Fig.48 It is a stacked diagram of XRPD patterns: (a) Phosphate Form A formed from THF – Batch HAL-G-26 (21); (b) Phosphate Form A formed from IPA – Batch HAL-G-26 (22); (c) Phosphate Form A after gravimetric moisture absorption – Batch HAL-G-26 (22) AD; (d) Phosphate Form A after 7 days of equilibrium in IPA – Batch HAL-G-32 (6); (e) Phosphate Form A after 7 days of exposure at 60°C – Batch HAL-G-30 (3); (f) Formula (I) free form – Batch LMA-U-133 (2);
[0152] Fig.49 is an optical micrograph of phosphate crystal form A-batch HAL-G-26 (21) formed from THF;
[0153] Fig.50 Phosphate Form A – Batch HAL-G-26 (21) formed from THF 1 H-NMR spectrum;
[0154] Fig.51 is the DSC spectrum of phosphate crystal form A-batch HAL-G-26 (21) formed from THF;
[0155] Fig.52 is the moisture absorption curve of phosphate crystal form A – batch HAL-G-26 (22) formed from IPA;
[0156] Fig.53 The following are stacked images of XRPD patterns: (a) sulfate salt form A formed from THF - batch HAL-G-26 (23); (b) sulfate salt form B formed from IPA - batch HAL-G-26 (24); (c) free form of formula (I) - batch LMA-U-133 (2);
[0157] Fig.54 is an optical micrograph of sulfate salt Form A-Batch HAL-G-26 (23) formed from THF; Fig.55 It is stacked 1 H-NMR spectra: (a) Sulfate salt form A formed from THF - batch HAL-G-26 (23); (b) Sulfate salt form B formed from IPA - batch HAL-G-26 (24);
[0158] Fig.56 is the TGA spectrum of sulfate salt form A-batch HAL-G-26 (23) formed from THF;
[0159] Fig.57 is the DSC spectrum of sulfate salt form A-batch HAL-G-26 (23) formed from THF;
[0160] Fig.58 is an optical micrograph of sulfate salt Form B – Batch HAL-G-26 (24) formed from IPA;
[0161] Fig.59 is the TGA spectrum of sulfate salt form B-batch HAL-G-26 (24) formed from IPA;
[0162] Fig.60 is the DSC spectrum of sulfate salt form B – batch HAL-G-26 (24) formed from IPA;
[0163] Fig.61The stacked images of XRPD patterns are as follows: (a) Tartrate Form A formed from THF - Batch HAL-G-26 (25); (b) Tartrate Form B formed from IPA - Batch HAL-G-26 (26); (c) Formula (I) free form - Batch LMA-U-133 (2);
[0164] Fig.62 It is stacked 1 H-NMR spectra: (a) Tartrate salt form A formed from THF - batch HAL-G-26 (25); (b) sulfate salt form B formed from IPA - batch HAL-G-26 (26), asterisks indicate unknown impurities;
[0165] Fig.63 is the DSC spectrum of the tartrate salt Form A-batch HAL-G-26(25) formed from THF;
[0166] Fig.64 is the TGA spectrum of the tartrate salt Form A-batch HAL-G-26 (25) formed from THF;
[0167] Fig.65 is the TGA spectrum of the tartrate salt Form B-batch HAL-G-26 (26) formed from IPA;
[0168] Fig.66 is the DSC spectrum of the tartrate salt Form B-batch HAL-G-26 (26) formed from IPA; Fig.67 The XRPD patterns are stacked: (a) p-toluenesulfonate salt form A formed from THF - batch HAL-G-26 (27), additional diffraction at 6.5° 2θ (marked as ↓); (b) p-toluenesulfonate salt formed from IPA - batch HAL-G-26 (28); (c) free form of formula (I) - batch LMA-U-133 (2);
[0169] Fig.68 is an optical micrograph of the p-toluenesulfonate salt Form A-Batch HAL-G-26 (27) formed from THF;
[0170] Fig.69 The p-toluenesulfonate salt, Form A, was formed from THF - batch HAL-G-26 (27) 1 H-NMR spectrum;
[0171] Fig.70 is the DSC spectrum of the p-toluenesulfonate salt Form A-Batch HAL-G-26(27) formed from THF;
[0172] Fig.71The figure is a stacked diagram of XRPD patterns: (a) p-toluenesulfonate salt form A formed from MeOH - batch HAL-G-26 (29); (b) citrate salt form A formed from IPA - batch HAL-G-26 (31); (c) citrate salt form B formed from THF - batch HAL-G-26 (30); (d) free form of formula (I) - batch LMA-U-133 (2);
[0173] Fig.72 It is stacked 1 H-NMR spectra: (a) Citrate salt Form A formed from MeOH - Batch HAL-G-26 (29); (b) Citrate salt Form B formed from THF - Batch HAL-G-26 (30);
[0174] Fig.73 is the TGA spectrum of citrate salt Form A-Batch HAL-G-26 (29) formed from MeOH;
[0175] Fig.74 is the DSC spectrum of citrate salt Form A-Batch HAL-G-26 (29) formed from MeOH;
[0176] FIG. 75 (a) is a TGA spectrum of citrate salt Form B-batch HAL-G-26 (30) formed from THF; FIG. 75 is a DSC spectrum of citrate salt Form B-batch HAL-G-26 (30) formed from THF; Fig.76 The following are stacked images of XRPD patterns: (a) hydrochloride salt form A formed from EtOH – batch HAL-G-26 (32); (b) hydrochloride salt form A formed from IPA – batch HAL-G-26 (33); (c) hydrochloride salt form A formed from THF – batch HAL-G-26 (34); (d) hydrochloride salt form A formed from EtOH at a 200 mg level – batch HAL-G-29 (3); (e) hydrochloride salt form A after gravimetric moisture sorption analysis – batch HAL-G-29 (3); (f) free form of formula (I) – batch LMA-U-133 (2); Fig.77 is the Raman spectrum: HCl salt form A - batch HAL-G-29 (3), formula (I) free form form A - batch LMA-U-133 (2). The peak positions marked "↓" represent unique Raman peaks, red curve = free form; Fig.78 is an optical micrograph of the hydrochloride salt Form A-batch HAL-G-26 (32) formed from EtOH; Fig.79 Liquid hydrochloride Form A – Batch HAL-G-26 (32) formed from EtOH 1 H-NMR spectrum;
[0177] Fig.80 is the DSC spectrum of the hydrochloride salt form A-batch HAL-G-26 (33) formed from IPA;
[0178] Fig.81 is the moisture absorption curve of the hydrochloride salt form A-batch HAL-G-29(3) formed from IPA;
[0179] Fig.82 The XRPD patterns are stacked: (a) the hydrochloride salt Form A formed from EtOH at 200 mg level - Batch HAL-G-29 (3); (b) the hydrochloride salt Form A - Batch HAL-G-32 (2) after equilibration in IPA for 7 days; (c) the hydrochloride salt Form A - Batch HAL-G-30 (1) after exposure to 60°C for 7 days;
[0180] Fig.83 The following are stacked images of XRPD patterns: (a) ethanesulfonate salt Form A formed from THF - batch HAL-G-26 (35); (b) free form of formula (I) - batch LMA-U-133 (2);
[0181] Fig.84 Ethysulfonate salt Form A - Batch HAL-G-26 (35) formed from THF 1 H-NMR spectrum;
[0182] Fig.85 is the DSC spectrum of ethanesulfonate salt Form A-batch HAL-G-26(35) formed from THF; Fig.86 The following are stacked images of XRPD patterns: (a) naphthoate salt Form A formed from THF - Batch HAL-G-26 (36); (b) naphthoate salt Form B after gravimetric moisture sorption analysis - Batch HAL-G-26 (36) AD; (c) Form B after 7 days of equilibration in IPA at room temperature - Batch HAL-G-32 (5); (d) Form B after 7 days of storage at 60°C - Batch HAL-G-30 (5); (e) Form C after equilibration in water at room temperature overnight - Batch HAL-G-31 (6); (f) free form of formula (I) - Batch LMA-U-133 (2);
[0183] Fig.87 Display stacked 1 H-NMR spectra: (a) naphthoate salt Form A formed from THF – batch HAL-G-26 (36); (b) naphthoate salt Form B slurried in IPA for 7 days – batch HAL-G-32 (5); (c) naphthoate salt Form C slurried in water overnight – batch HAL-G-31 (6);
[0184] Fig.88TGA spectra showing stacking of: (a) naphthoate salt Form A formed from THF – Batch HAL-G-26 (36); (b) naphthoate salt Form B slurried in IPA for 7 days – Batch HAL-G-32 (5); (c) naphthoate salt Form C slurried in water overnight – Batch HAL-G-31 (6);
[0185] FIG89( a ) is a DSC spectrum: (a) naphthoate salt form A formed from THF - batch HAL-G-26 (36); FIG89( b ) is a DSC spectrum: naphthoate salt form B slurried in IPA for 7 days - batch HAL-G-32 (5); naphthoate salt form C slurried in water overnight - batch HAL-G-31 (6);
[0186] Fig.90 is the moisture absorption curve of naphthoate salt Form A – Batch HAL-G-26 (36) formed from THF;
[0187] Fig.91 The following are stacked images of XRPD patterns: (a) Form A succinate salt formed from THF - Batch HAL-G-26 (37); (b) Form A succinate salt formed from THF at 200 mg level - Batch HAL-G-29 (1); (c) Form A - Batch HAL-G-29 (1) AD after moisture sorption analysis; (d) Form A - Batch HAL-G-32 (4) after equilibration in IPA for 7 days; (e) Form A - Batch HAL-G-30 (4) after storage at 60°C for 7 days; (f) Formula (I) free form - Batch LMA-U-133 (2);
[0188] Fig.92 is an optical micrograph of the succinate salt Form A-Batch HAL-G-26 (37) formed from THF;
[0189] Fig.93 Succinate Form A - Batch HAL-G-26 (37) was formed from THF 1 H-NMR spectrum;
[0190] Fig.94 is the DSC spectrum of the succinate salt Form A-batch HAL-G-26 (37) formed from THF;
[0191] Fig.95 is the moisture absorption curve of the succinate salt form A-batch HAL-G-29(1) formed from THF;
[0192] Fig.96The following are stacked images of XRPD patterns: (a) Form A glutarate salt formed from THF - batch HAL-G-26 (39); (b) free form of formula (I) - batch LMA-U-133 (2);
[0193] Fig.97 is an optical micrograph of Form A of the glutarate salt formed from THF - batch HAL-G-26 (39);
[0194] Fig.98 Form A of the glutarate salt formed from THF – batch HAL-G-26 (39) 1 H-NMR spectrum;
[0195] Fig.99 is the DSC spectrum of Form A of the glutarate salt formed from THF - batch HAL-G-26 (39); Fig.100 The following are stacked images of XRPD patterns: (a) glutamate salt form A formed from THF - batch HAL-G-26 (40); (b) glutamate salt form A formed from THF at 200 mg level - batch HAL-G-29 (2); (c) form A after 7 days of equilibration in IPA - batch HAL-G-32 (3); (d) form A after 7 days of storage at 60°C - batch HAL-G-30 (4); (e) form A after moisture absorption analysis - batch HAL-G-29 (2) AD; (f) form A stored at 95% RH for 5 hours - batch HAL-G-32 (11); (g) free form of formula (I) - batch LMA-U-133 (2);
[0196] Fig.101 is an optical micrograph of Form A of the glutamate salt formed from THF - batch HAL-G-26 (40);
[0197] Fig.102 Display stacked 1 H-NMR spectra: (a) Glutamate salt form A formed from THF - batch HAL-G-26 (40); (b) Glutamate salt form B - batch HAL-G-32 (11) after storage of form A at 95% RH for 5 hours. DETAILED DESCRIPTION
[0198] The following examples illustrate the methods and compounds of the present invention. It should be understood, however, that the present invention is not limited to the specific examples.
[0199] Unless otherwise stated, commercially available reagents and solvents were used. Formula (I) was synthesized according to US2009298809.
[0200] Example 1 Preparation of 70 mg grade salt
[0201] Albany Molecular Research, Inc. (AMRI) completed a salt screening of Formula (I). This study was conducted through a series of salt formation experiments using multiple solvent and counterion combinations. The selected crystalline salt forms produced during the screening process were analyzed by XRPD, and the crystalline form of each salt was classified as A, B or C based on the XRPD results.
[0202] Approximately 70 mg of formula (I) (batch LMA-U-133 (2)) was weighed into an 8-mL or 20-mL vial containing a magnetic stirring bar. To the vial, a primary solvent (MeOH, EtOH, IPA or THF) was added to ensure dissolution at elevated temperatures. After dissolution, 1.05 equivalents of acid were added dropwise to obtain a 0.25 or 0.50 M solution (Table 1). The resulting mixture was stirred at elevated temperature for about 10-15 min, then cooled to room temperature at a rate of 20°C / h and stirred overnight at room temperature. After cooling, the observed solids were separated by filtration and dried in vacuo at room temperature overnight. After cooling, the solid-free sample was evaporated under a nitrogen atmosphere and dried in vacuo at room temperature overnight. The analytical results of the resulting solids are shown in Table 1.
[0203] Table 1: Analysis results of 70 mg salt
[0204]
[0205]
[0206] - not analyzed or not applicable, (x) indicates exothermic [ ] other solvents provided in the same form, data not collected
[0207] Table 1 (continued): Analysis results of 70 mg level salt
[0208]
[0209] - Not analyzed or not applicable
[0210] Example 2 Preparation of 200 mg level salt
[0211] In order to prepare more product for further characterization, the HCl salt, glutamate and succinate of formula (I) were prepared at a larger scale. Approximately 200 mg of formula (I) (batch LMA-U-133 (2)) was weighed into an 8 mL or 40 mL vial containing a magnetic stirring bar. To the vial, the main solvent (EtOH or THF) was added to ensure dissolution at high temperature. After dissolution, 1.05 equivalents of acid were added dropwise to obtain a 0.5 M solution. The resulting mixture was stirred at high temperature for about 10-15 min, then cooled to room temperature at a rate of 20 ° C / h, and stirred at room temperature overnight. After cooling, the observed solid was separated by filtration and dried in vacuo at room temperature overnight. The experimental details and results are shown in Table 2.
[0212] Table 2: Experimental details and results of salt formation at 200 mg level
[0213]
[0214] Example 3 Characterization of free form and salt of formula (I)
[0215] 1. Methods
[0216] (1) Characterization
[0217] The free base material of formula (I) provided by AMRI [Batch LMA-U-133(2)] and the selected crystalline salt forms produced during the screening process were analyzed by XRPD, Raman, microscopy, DSC and TGA. 1 H NMR and / or ICP / OES to determine the stoichiometry of the salt and to determine if degradation has occurred during salt formation.
[0218] (2) TGA gravity solubility analysis
[0219] The water solubility of the selected salts provided in the 70 mg scale experiment was estimated by the following weight method. Approximately 20 mg of each salt was weighed into a 2 mL HPLC vial. Then, 50 μL of deionized water was added to each vial containing a small magnetic stirring bar. If dissolution was observed, the sample was stored in a protective cover overnight and checked for precipitation the next day. After adding up to 250 μl of water to the insoluble sample, it was stirred overnight under ambient conditions to reach equilibrium. Then, these samples were centrifuged and filtered, and 50 μL of the saturated solution was aliquoted to a constant weight TGA analyzer. On the TGA analyzer, each sample was heated and kept at high temperature until all the solvents were dried and removed. Then, the resulting dried solid and aliquoted volumes of each saturated solution were used to estimate the solubility. The experimental results are shown in Table 3.
[0220] Table 3: Gravimetric water solubility determination
[0221]
[0222] - Not analyzed or not applicable
[0223] Table 3 (continued): Gravimetric water solubility determination of salts formed on 70 mg scale
[0224]
[0225] * Initial dissolved solids and ppt produced after 2 hours at RT.
[0226] - Not analyzed or not applicable
[0227] (3) Water solubility study
[0228] Approximately 20 mg of the free form, methanesulfonate, hydrochloride, succinate, glutamate, naphthoate, and phosphate salts of Formula (I) were weighed into individual HPLC vials equipped with a magnetic stir bar and 0.05 mL of deionized water was added. If dissolution was observed, the approximate solubility was recorded. If no dissolution was observed, the slurry was stirred overnight at ambient temperature. The supernatant of each slurry was obtained using a centrifugal filter. The pH of each solution was tested and compared to the HPLC calibration curve ( Figure 6 ) to determine the equilibrium solubility. The filtered solid was analyzed by XRPD to confirm the crystalline form (Table 4).
[0229] Table 4: Water solubility of salts and free forms of formula (I)
[0230]
[0231] * Inadequate recovery of solids from slurry
[0232] - Not analyzed or not applicable
[0233] (4) Stability at high temperatures
[0234] Approximately 10 mg of the free form, methanesulfonate, hydrochloride, succinate, glutamate, naphthoate and phosphate salts of Formula (I) were weighed into separate 4 mL vials and stored in an oven at 60°C and ambient pressure. After 7 days, the solids were analyzed by XRPD to check for crystalline morphology conversion and 1 H-NMR analysis of the solid degradation (Table 5).
[0235] Table 5: High temperature stability of salt forms of formula (I)
[0236]
[0237] * Similar form to Form B with additional reflections at 2θ of 13°, 13.5° and 14.5°.
[0238] (5) Organic pulping experiment
[0239] Approximately 30 mg of the free form, methanesulfonate, hydrochloride, succinate, glutamate, naphthoate and phosphate salts of Formula (I) were weighed into individual HPLC vials equipped with a magnetic stir bar. THF or IPA was added to obtain a free-flowing slurry. After 7 days of ambient equilibration, each slurry was centrifuged using a 0.45 μm nylon centrifugal filter to obtain a solid form and dried at ambient temperature, about 30 Hg. After drying overnight, each was analyzed by XRPD to check for crystalline morphology conversion and by 1 H-NMR analysis of the solid degradation (Table 6).
[0240] Table 6: Organic slurry of salt of formula (I)
[0241]
[0242] (6) Relative humidity research
[0243] Approximately 30 mg of monoglutamate Form A [Batch HAL-G-29(2)] was stored in a dry open small glass container containing a saturated aqueous solution of Na2HPO4·12H2O to achieve a relative humidity of 95%. After exposure for 5 hours, the solid deliquesced and the sample was exposed to the laboratory environment (20% RH) overnight. The resulting dry solid was characterized by XRPD, DSC and TGA.
[0244] 2. Results
[0245] (1) Formula (I) free form
[0246] Crystalline Form A
[0247] The free form of formula (I) [Batch LMA-U-133 (2)] obtained from the Medicinal Chemistry Department of AMRI was subjected to XRPD analysis to obtain a crystal diffraction pattern, and the free form was designated as Form A ( Figure 7 ). It was observed that the crystal form has Raman activity, such as Figure 8 shown. 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed two unknown impurity resonances at 1.2 ppm and 4.0 ppm ( Fig. 9 ). DSC thermal analysis showed an endotherm at 242°C, indicating melting ( Fig.10 ). TGA analysis showed no weight loss. Water sorption analysis showed that the material was non-hygroscopic, with less than 0.2 wt% water adsorbed during the entire hygroscopic operation ( Fig.11 After the moisture absorption operation, the XRPD pattern of the dry material was consistent with the XRPD pattern of the raw material, indicating that no crystal form transformation occurred during the experiment ( Figure 7 ). Optical microscopy of the free form under cross-polarized light shows birefringent irregularly shaped particles ( Fig.12 After 24 hours of equilibration, the water solubility was observed to be 2.0 mg / mL at pH 9.3, and there was no change in the crystalline form as evaluated by XRPD ( Figure 7 After storage at 60°C for 7 days, XRPD showed no signs of crystalline form conversion, demonstrating that Form A is stable. The results obtained by characterizing Form A are summarized in Table 7.
[0248] Form B
[0249] The XRPD pattern of HAL-G-32(7) obtained after slurrying Form A in IPA (isopropyl alcohol) at room temperature for 7 days is different from the diffraction pattern of Form A ( Figure 7 ). 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed that it contained approximately 15.7 wt% IPA ( Fig. 9 ). TGA analysis showed a step transition at 90-130°C, corresponding to a 16.0 wt% loss, which is comparable to the theoretical IPA content (16.8 wt%) of the mono-IPA solvate of formula (I) ( Fig.13 Further DSC thermal analysis showed that the two endothermic transitions at 116 and 268 °C were attributed to desolvation and melting ( Fig.14 ). The results obtained by characterizing Form B are listed in Table 7. The results obtained by characterizing the free form of Formula (I) indicate that it exists in two unique crystalline forms, including an anhydrate (Form A) and a mono-IPA solvate (Form B). Considering that the melting temperature of Form A was determined to be 242°C, it can be further assumed that an additional non-independent solid form of Formula (I) may exist, which melts at 268°C.
[0250] (2) Adipic acid
[0251] In the 70 mg scale sample, batch HAL-G-26 (1) isolated from EtOH and batch HAL-G-26 (2) isolated from IPA showed the same single crystal XRPD pattern, which is unique compared to the free form of formula (I) and all other synthetic salts ( Fig.15 This solid form was also observed to be crystalline by optical microscopy under cross-polarized light, showing birefringent needle-like particles ( Fig.16 ). Batch HAL-G-26(2) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 0.5:1, indicating the formation of the hemiadipate salt of formula (I) designated as Form A. 1 Further examination of the H-NMR spectrum showed approximately 0.4 wt% residual IPA ( Fig.17). DSC thermal analysis of Form A showed a single endothermic peak at 260°C, which was attributed to the melting of the crystalline salt ( Fig.18 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A hemi-salt in water was visually estimated to be in excess of 400 mg / mL. Although the salt exhibited desirable physical properties, it was not chosen for further characterization due to the prevalence of counterion deficiency in pharmaceutical products. The results obtained by characterizing Form A are summarized in Table 7.
[0252] (3) Benzenesulfonic acid
[0253] Crystalline Form A
[0254] The XRPD pattern of single crystals of batch HAL-G-26 (3) isolated from THF in a 70 mg scale sample is different from the diffraction patterns of the free form of formula (I) and all other synthetic salts ( Fig.19 ). Under cross-polarized light, this solid form was observed to be crystalline. 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the mono-benzenesulfonate salt of formula (I) designated as Form A ( Fig. 20 ). DSC thermal analysis of Form A showed an endothermic peak at 260°C, which was attributed to melting, followed by decomposition at 381°C ( Fig.21 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A mono-salt in water was visually estimated to be over 400 mg / mL. The results obtained by characterizing Form A are summarized in Table 7.
[0255] Form B
[0256] The XRPD pattern of single crystal of batch HAL-G-26 (3) isolated from IPA in the 70 mg scale sample is different from the diffraction patterns of the free form and benzenesulfonate salt form A of formula (I) ( Fig.19 ). This solid form was also observed to be crystalline under cross-polarized light ( Fig. 22 ). Batch HAL-G-26(4) 1 H-NMR analysis confirmed the chemical structure of Formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the mono-besylate salt of Formula (I) designated Form B. 1 Further examination of the H-NMR spectrum showed approximately 0.1 wt% residual IPA ( Fig. 20 ). TGA analysis of Form B showed no weight loss. Further analysis of Form B by DSC showed minor transitions at 188°C and 227°C, followed by melting at 262°C ( Fig.23Since complete dissolution was observed, the solubility of Form B mono-salt in water was visually estimated to be in excess of 400 mg / mL.
[0257] The characterization results of the benzenesulfonate salt of formula (I) show that it exists in two crystalline monosalt forms (form A and form B). Since the genotoxic impurities separated from the alcohol solvent should require additional testing requirements, this counterion was not selected for further characterization. The results obtained by characterizing form B are summarized in Table 7.
[0258] (4) Hydrobromic acid
[0259] In the 70 mg scale sample, batch HAL-G-26 (5) isolated from THF and batch HAL-G-26 (6) isolated from IPA had the same single crystal XRPD pattern, which was different from the free form of formula (I) and all other synthetic salts ( Fig.24 ). This solid form also showed evidence of crystallinity under cross-polarized light ( Fig.25 ). Batch HAL-G-26(6) 1 The H-NMR spectrum is consistent with the chemical structure of formula (I) and shows about 0.5 wt% residual IPA ( Fig.17 ). ICP / OES confirmed the formation of a single salt. Thermal analysis of the bromide salt by DSC showed a single endothermic peak at 333 °C, which was attributed to the melting of the crystalline salt ( Fig.26 ). No weight loss was observed by TGA. The solubility of the bromide salt in water was estimated to be 56.1 mg / mL using TGA gravimetric methods. Although this salt showed the desired water solubility, it was not selected due to its lack of crystallinity and general safety issues associated with hydrobromide salts. The results obtained by characterizing Form A are summarized in Table 7.
[0260] (5) Fumaric acid
[0261] In the 70 mg scale sample, batch HAL-G-26 (9) isolated from THF and batch HAL-G-26 (10) isolated from IPA had the same single crystal XRPD pattern, which was different from the free form of formula (I) and all other synthetic salts ( Fig. 27 ). Examination of the solid under cross-polarized light revealed birefringent particles with irregularly shaped crystal habits ( Fig.28 ). Batch HAL-G-26(9) 1 H-NMR analysis confirmed the chemical structure of Formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the monofumarate salt of Formula (I) designated Form A. 1 Further inspection of the H-NMR spectrum showed approximately 1.6 wt% THF and 0.4 wt% EtOH ( Fig.29DSC thermal analysis of the fumarate salt showed a single endothermic peak at 293 °C, which was attributed to the melting of the crystalline salt ( Fig.30 ). No weight loss was observed by TGA. Because complete dissolution was observed, the solubility of Form A in water was ≥400 mg / mL by visual estimation. Due to the potential for isomerization to maleic acid leading to undesirable toxicological effects, this salt was not chosen for further characterization. The results obtained by characterizing Form A are summarized in Table 7.
[0262] (6) Benzoic acid
[0263] In the 70 mg scale sample, batch HAL-G-26 (11) isolated from THF and batch HAL-G-26 (12) isolated from IPA had the same single crystal XRPD pattern, which was different from the free form of formula (I) and all other synthetic salts ( Fig.31 Examination of the solid under cross-polarized light revealed birefringent particles with needle-like and knife-like crystal habits ( Fig.32 ). Batch HAL-G-26(12) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the monobenzoate salt of formula (I) designated as Form A ( Fig.33 ). TGA analysis showed no weight loss, and by DSC, two endothermic transitions at 261°C and 320°C were observed, attributed to melting and decomposition (Figure 34). Using the TGA weight method, the solubility of the benzoate salt in water was estimated to be 12.5 mg / mL. Although Form A was observed to be crystalline and showed better solubility than the free form, this salt was not selected due to the lack of prevalence in pharmaceuticals and general safety issues associated with benzoate salts. The results obtained by characterizing Form A are summarized in Table 7.
[0264] (7) Methanesulfonic acid
[0265] In the 70 mg scale sample, batch HAL-G-26 (13) isolated from THF and batch HAL-G-26 (14) isolated from IPA showed consistent single crystal XRPD patterns, which showed differences compared to the diffraction patterns of the free form of formula (I) ( Fig.35 ). Examination of batch HAL-G-26 (13) under cross-polarized light showed birefringent particles with needle-like and knife-like morphologies ( Fig.36 ). Batch HAL-G-26(13) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the mono-methanesulfonate salt of formula (I) designated as Form A ( Fig.37). DSC thermal analysis of the mesylate salt showed a single endothermic peak at 302 °C, which was attributed to the melting of the crystalline salt ( Fig.38 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A in water was visually determined to be ≥ 400 mg / mL. This salt was selected for comprehensive characterization based on thermal stability, high crystallinity, and improved water solubility compared to the free form.
[0266] Form A was observed to be moderately hygroscopic by gravimetric moisture sorption, absorbing up to 4.6 wt% water at 80% RH, followed by a sharp increase to 8.8 wt% at 90% RH ( Fig.39 ). XRPD analysis of the sample after moisture absorption and drying showed that the crystal pattern was consistent with that of the sample before drying, indicating that no crystal form transformation occurred during the moisture absorption experiment ( Fig.35 After equilibration in THF at room temperature and storage at 60°C for 7 days, Form A showed no signs of crystal transformation, indicating that Form A is stable ( Fig.35 ). These findings indicate that Form A is the thermodynamically favorable crystalline form of the mono-methanesulfonate of Formula (I). The results obtained by characterizing Form A are summarized in Table 7.
[0267] (8) L-Malic acid
[0268] In 70 mg scale samples, batch HAL-G-26 (15) isolated from THF and batch HAL-G-26 (16) isolated from IPA showed the same single crystal XRPD pattern, which is different from the free form of formula (I) and all other synthetic salts ( Fig.40 Examination of the solid under cross-polarized light provided further evidence of crystallinity ( Fig.41 ). Batch HAL-G-26(16) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 0.4:1, indicating the formation of a hemi-malate salt of formula (I) designated as Form A ( Fig.42 ). 1 Further inspection of the H-NMR spectrum showed approximately 0.4 wt% IPA and 1.1 wt% EtOH ( Fig.42 ). TGA analysis showed a 2.0 wt% loss at 140°C to 200°C, which was attributed to the loss of IPA and EtOH ( Fig.43 By DSC, two endothermic transitions were observed at 218 °C and 276 °C, which were attributed to the melting and decomposition of the salt ( Fig.44 ). Since complete dissolution was observed, the solubility of the malate salt in water was visually estimated to be ≥ 80 mg / mL. Although the salt exhibited desirable physical properties, it was not chosen for further characterization due to its limited thermal stability compared to the free form. The results obtained by characterizing Form A are summarized in Table 7.
[0269] (9) Sorbic acid
[0270] In a 70 mg scale sample, batch HAL-G-26 (20) isolated from IPA provided a single crystal XRPD pattern that was distinct from the free form of formula (I) and all other synthesized salts ( Fig.45 ). Examination of the solid under cross-polarized light provided further evidence of crystallinity. 1 H-NMR analysis showed approximately 2.3 wt% IPA and an acid:API ratio of 0.9:1, indicating the formation of the mono-sorbate salt of formula (I) designated Form A. 1 Further inspection of the H-NMR spectrum showed several impurity resonances at 1.3, 1.9, 2.4, 3.6, and 4.3 ppm ( Fig.46 ). TGA analysis showed a continuous weight loss at a temperature program of 30°C to 230°C. Further DSC testing showed two major endotherms at 136°C and 173°C and several minor transitions, which may be attributed to the presence of impurities and / or instrumental errors ( Fig.47 Because complete dissolution was observed, the solubility of Form A in water was visually estimated to be ≥200 mg / mL. Due to the prevalence of impurities observed in the analysis and the lack of counterions in the drug product, this salt was not chosen for further characterization. The results obtained by characterizing Form A are summarized in Table 7.
[0271] (10) Phosphate
[0272] In the 70 mg scale sample, batch HAL-G-26 (21) isolated from THF and batch HAL-G-26 (22) isolated from IPA showed consistent crystalline XRPD patterns ( Fig.48 ). The crystallinity of this unique solid was confirmed by examination under cross-polarized light ( Fig.49 ). Batch HAL-G-26(21) 1 The H-NMR spectrum is consistent with the chemical structure of formula (I) and does not show any residual solvent ( Fig.50 ). ICP / OES confirmed the formation of a single salt. DSC thermodynamic analysis of batch HAL-G-26 (22) showed a single endothermic peak at 276°C, which was attributed to the melting of the crystalline salt ( Fig.51 ), and no weight loss was observed by TGA. After slurrying overnight in room temperature water, the solubility of Form A in water was determined by HPLC to be 52 mg / mL. Considering that the thermal stability and water solubility of Form A are improved compared to the free form, this salt was selected for comprehensive characterization.
[0273] Form A was observed to be slightly hygroscopic at 60% RH, absorbing up to 1.1 wt% of water, and 2.4 wt% of water at 90% RH ( Fig.52 ). XRPD analysis of the sample after moisture absorption and drying showed that the crystal pattern was consistent with that of the sample before drying, indicating that the crystal form A did not undergo crystal form transformation during the moisture absorption experiment ( Fig.48 After equilibration in IPA at room temperature and storage at 60°C for 7 days, Form A was observed to be stable ( Fig.48 The above experimental results show that Form A is a thermodynamically favorable crystalline form of the monophosphate of formula (I). The results obtained by characterizing Form A are summarized in Table 7.
[0274] (11) Sulfuric acid
[0275] Crystalline Form A
[0276] In a 70 mg scale sample, batch HAL-G-26 (23) isolated from THF gave a crystalline XRPD pattern that was distinct from that of the free form of formula (I) and all other synthesized salts ( Fig.53 The solid form exhibits birefringent needle-shaped particles under cross-polarized light ( Fig.54 ). Batch HAL-G-26(23) 1 The H-NMR spectrum is consistent with the chemical structure of formula (I) and shows approximately 5.4 wt% EtOH ( Fig.55 ). ICP / OES confirmed the formation of a single salt, and the solubility of the salt in water was estimated to be 18.9 mg / mL. TGA analysis showed a step transition from 140°C to 190°C, which may be attributed to the reduction in the combined weight of 1.4 wt% water or EtOH ( Fig.56 The DSC spectrum of Form A shows an endothermic transition at 174°C, corresponding to a weight loss event observed by TGA, followed by a melting event at 316°C ( Fig.57 ). To elucidate the 174 °C transition, additional DSC experiments were performed in which the sample was heated to 210 °C twice to ensure completion of the initial endothermic event. Subsequent XRPD analysis of the sample showed conversion to an amorphous solid, and the corresponding 1 The H-NMR spectrum showed signs of degradation. Based on the results, further studies should be needed to determine whether the salt is solvated with water or EtOH. The results obtained by characterizing Form A are summarized in Table 7.
[0277] Form B
[0278] In a 70 mg scale sample, batch HAL-G-26 (24) isolated from IPA gave a crystalline XRPD pattern that was different from the diffraction patterns of the free form and sulfate salt Form A of Formula (I) ( Fig.53The crystallinity of this solid form was confirmed by optical microscopy ( Fig.58 ). Batch HAL-G-26(24) 1 The H-NMR spectrum is consistent with the chemical structure of formula (I) and shows approximately 1.4 wt% IPA and 5.4 wt% EtOH ( Fig.55 ). ICP / OES confirmed the formation of a single salt, and the solubility of the salt in water was estimated to be 69.2 mg / mL. TGA analysis showed a step transition from 160°C to 220°C, which may be attributed to the reduction in the combined weight of 2.8 wt% water or EtOH ( Fig.59 The DSC spectrum of Form B shows an endothermic transition at 215 °C, corresponding to a weight loss event observed by TGA, followed by a melting event at 303 °C ( Fig.60 To elucidate the 215 °C transition, additional DSC experiments were performed in which the sample was heated to 240 °C twice to ensure completion of the initial endothermic event.
[0279] The XRPD analysis of the sample subsequently showed conversion to an amorphous solid, and the corresponding 1H-NMR spectrum showed signs of degradation. According to the results, further research should be required to determine whether the salt is solvated with water or EtOH. The results obtained from the characterization of the sulfate salt of formula (I) indicate that there are two monosalt crystalline forms (form A and form B). Since it is possible to form a solvate, this counterion is not selected for further characterization. The results obtained by characterizing form B are summarized in Table 7.
[0280] (12) L-Tartaric acid
[0281] Crystalline Form A
[0282] In a 70 mg scale sample, batch HAL-G-26 (25) isolated from THF gave a crystalline XRPD pattern that was distinct from that of the free form of formula (I) and all other synthesized salts ( Fig.61 The crystallinity of the sample was also confirmed by cross-polarized light detection. 1 H-NMR estimated the stoichiometry of the solid to be 0.5:1 ( Fig.62 ). These findings indicate the formation of a hemitartrate salt of formula (I) designated Form A. 1 Further inspection of the H-NMR spectrum showed resonances of approximately 1.0 wt% EtOH and trace impurities ( Fig.62 DSC thermoanalysis of the tartrate salt showed a broad endotherm at 72 °C attributed to the release of EtOH, followed by an endotherm at 283 °C attributed to melting and decomposition ( Fig.63 ). TGA analysis showed a weight loss of 2.8 wt% attributed to the loss of EtOH ( Fig.64). Since complete dissolution was observed, the solubility of Form A in water was estimated by visual inspection to be ≥90 mg / mL. The results obtained by characterizing Form A are summarized in Table 7.
[0283] Form B
[0284] In a 70 mg scale sample, batch HAL-G-26 (26) isolated from IPA gave a crystalline XRPD pattern that was unique compared to the free form and tartrate salt Form A of Formula (I) ( Fig.61 The crystallinity of the sample was also confirmed by cross-polarized light detection. 1 H-NMR estimated the stoichiometry of the solid to be 0.5: 1. These findings indicate the formation of a hemitartrate salt of formula (I) designated Form B. 1 Further inspection of the H-NMR spectrum showed approximately 2.3 wt% IPA and 0.5 wt% EtOH ( Fig.62 ). TGA analysis showed that the step transition from 160°C to 220°C was attributed to the loss of 10.2 wt% water ( Fig.65 This result is comparable to the theoretical water content of the dihydrate hemitartrate of formula (I), which is 9.2 wt%. Two endothermic transitions were observed by DSC at 198°C to 284°C, which are attributed to the dehydration and melting of the salt ( Fig.66 ). Since complete dissolution was observed, the solubility of Form B in water was estimated by visual inspection to be ≥120 mg / mL. The results obtained from the characterization of the tartrate salt of Formula (I) indicate the presence of a crystalline anhydrate and a hydrate hemi-salt form. Due to the possibility of hydrate formation, which can pose stability challenges during long-term storage, this counterion was not selected for further characterization. The results obtained from the characterization of Form B are summarized in Table 7.
[0285] (13) p-Toluenesulfonic acid
[0286] In 70 mg scale samples, batch HAL-G-26 isolated from THF (27) and batch HAL-G-26 isolated from IPA (28) provided similar single crystal XRPD patterns except for one additional small reflection at 6.5° 2θ ( Fig.67 ). Examination of batch HAL-G-26 (27) under cross-polarized light revealed birefringent particles with needle-like and knife-like morphologies ( Fig.68 ). Batch HAL-G-26(27) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the mono-p-toluenesulfonate salt of formula (I) designated as Form A ( Fig.69 DSC thermoanalysis of the p-toluenesulfonate salt showed a single endothermic event at 271 °C, which was attributed to the melting of the crystalline salt ( Fig.70 ), and no weight loss was observed by TGA. The solubility of Form A in water was estimated to be 20.3 mg / mL by TGA gravimetric method. Since the genotoxic impurities separated from the alcohol solvent should require other testing requirements, this salt was not selected for further characterization. The results obtained by characterizing Form A are summarized in Table 7.
[0287] (14) Citric acid
[0288] Crystalline Form A
[0289] In 70 mg scale samples, batch HAL-G-26 (29) isolated from MeOH and batch HAL-G-26 (31) isolated from IPA gave identical crystalline XRPD patterns, which were different compared to the free form of formula (I) and all other synthesized salts ( Fig.71 ). The crystallinity of the sample was also confirmed by cross-polarized light detection. 1 H-NMR analysis showed an acid:API ratio of 0.5:1, indicating the formation of a hemi-salt. 1 Further inspection of the H-NMR spectrum showed approximately 2.1 wt% EtOH ( Fig.72 ). TGA analysis showed a step transition from 150°C to 210°C, which was attributed to the loss of 11.1 wt% water ( Fig.73 This result is comparable to the theoretical water content of the dehydrated hemi-citrate of formula (I) of 8.8 wt%. By DSC, two endothermic transitions were observed at 177°C and 246°C, which are attributed to the dehydration and melting of the salt ( Fig.74 ). Using TGA gravimetric method, the solubility of Form A in water was estimated to be 54.0 mg / mL. The results of the characterization of Form A are summarized in Table 7.
[0290] Form B
[0291] In a 70 mg scale sample, batch HAL-G-26 (30) isolated from THF provided a unique XRPD pattern ( Fig.71 ). Differences observed in the XRPD pattern compared to Form A include missing reflections at 4.7, 16, and 17° 2θ. The crystallinity of the solid was also confirmed by examination under cross-polarized light. 1 H-NMR analysis showed an acid:API ratio of 0.5:1, indicating the formation of a hemi-salt. 1 Further inspection of the H-NMR spectrum showed that approximately 1.3 wt% EtOH ( Fig.72 DSC analysis showed a single melting endotherm at 237 °C and by TGA no weight loss was observed until the onset of melting / decomposition at 192 °C ( Figure 75(a) and75(b) ). Since complete dissolution was observed, the solubility of Form B in water was estimated by visual inspection to be ≥190 mg / mL. After the solution was stored overnight under ambient conditions, precipitation was observed, indicating the formation of a hydrate. The results obtained by characterization of the citrate salt of Formula (I) indicate the presence of a crystalline anhydrate and a hydrate hemi-salt form. Although the citrate salt provides improved water solubility compared to the free form, due to the potential for hydrate formation (which would typically present stability challenges during long-term storage), this counterion was not selected for further characterization. The results obtained by characterizing Form B are summarized in Table 7.
[0292] (15) Hydrochloric acid
[0293] In the 70 mg scale sample, batches of HAL-G-26 (32) isolated from EtOH, batches of HAL-G-26 (33) isolated from IPA, and batches of HAL-G-26 (34) isolated from THF showed consistent crystalline XRPD spectra, which were different from the pattern of the free form of formula (I) ( Fig.76 ). This unique solid form can also be obtained from EtOH at a 200 mg scale. The Raman spectrum of this material also shows differences compared to the free form spectrum ( Fig.77 ). Cross-polarized light examination revealed birefringent irregular particles ( Fig.78 ). Batch HAL-G-26(32) 1 The H-NMR spectrum is consistent with the chemical structure of formula (I) and shows that 0.2 wt% EtOH ( Fig.79 ). ICP / OES confirmed the formation of a monosalt. DSC thermal analysis of batch HAL-G-26 (33) showed two endothermic peaks at 349°C and 367°C, which were attributed to the melting and decomposition of the crystalline salt ( Fig.80 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A in water was estimated to be ≥209 mg / mL by visual inspection. The hydrochloride salt was selected for comprehensive characterization, considering that the salt has improved thermal stability and water solubility compared to the free form.
[0294] Form A was observed to be slightly hygroscopic at 60% RH, absorbing up to 0.8 wt% of water, and at 90% RH, absorbing up to 1.3 wt% of water ( Fig.81 ). XRPD analysis of the sample after moisture absorption and drying showed that the crystal pattern was consistent with that of the sample before drying, indicating that no crystal form transformation occurred during the moisture absorption experiment ( Fig.76 ). It was observed that after Form A was equilibrated in IPA at room temperature and stored at 60°C for 7 days, there was no sign of crystal transformation, indicating that Form A is stable ( Fig.82The above experimental results show that Form A is the thermodynamically favorable crystalline form of the monohydrochloride salt of Formula (I). The results obtained by characterizing Form A are summarized in Table 7.
[0295] (16) Ethylsulfonic acid
[0296] In a 70 mg scale sample, batch HAL-G-26 (35) isolated from THF gave a crystalline XRPD pattern that was distinct from that of the free form of formula (I) and all other synthesized salts ( Fig.83 ). Examination of the solid under cross-polarized light showed birefringent particles, confirming crystallinity. Batch HAL-G-26 (35) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of the mono-ethanesulfonate salt of formula (I) designated as Form A ( Fig.84 ). TGA analysis showed no weight loss, and by DSC, a single melting transition was observed at 290 °C ( Fig.85 ). Because complete dissolution was observed, the solubility of the ethanesulfonate salt in water was estimated by visual inspection to be ≥380 mg / mL. Although Form A exhibited the desired physical characteristics, this salt was not selected for further characterization due to the genotoxic impurities separated from the alcohol solvent that would require additional testing requirements. The results obtained by characterizing Form A are summarized in Table 7.
[0297] (17) 1-Hydroxy-2-naphthoic acid
[0298] Crystalline Form A
[0299] In a 70 mg scale sample, batch HAL-G-26 (36) isolated from THF provided a unique crystalline XRPD pattern that was different from the diffraction pattern of the free form of formula (I) ( Fig.86 ). The crystallinity of this unique solid was confirmed by examination under cross-polarized light. 1 H-NMR analysis showed an acid:API ratio of 1.1:1, indicating the formation of the mono-naphthoate salt of formula (I) and 5.6 wt% residual THF ( Fig.87 TGA analysis showed a broad weight loss transition (2.9 wt%) at 80-190 °C, which was attributed to the loss of residual THF, followed by a step transition, equivalent to a 1.1 wt% loss ( Fig.88 Further DSC analysis showed a slight exotherm at the same temperature (200 °C) due to the TGA step transition, followed by melting at 220 °C ( Figure 89(a) and 89(b)). Further studies may be needed to clarify the exothermic transition at 200 °C. Using TGA gravimetric methods, the solubility of the naphthoate salt was initially estimated to be 4.7 mg / mL. The solid obtained from the experiment was not analyzed by XRPD, but based on the solubility results described below, it can be concluded that 1-hydroxy-2-naphthoate salt also has another crystalline form (Form C). Due to its good water solubility and stability, 1-hydroxy-2-naphthoate salt was selected for comprehensive characterization
[0300] The test found that Form A is moderately hygroscopic, absorbing up to 1.5% wt% of water at 60% RH and up to 2.5% wt% of water at 90% RH ( Fig.90 ). During the desorption process, the curve stabilized at about 2.0 wt% water at 75% to 55% RH, indicating the formation of a hemihydrate (theoretical water content = 1.8 wt%). When the relative humidity was further reduced to 45% RH, a long equilibrium period was observed, indicating that dehydration occurred. The dried solid obtained after the moisture absorption experiment showed a unique XRPD pattern compared to the diffraction pattern of Form A ( Fig.86 ). 1 H-NMR analysis also confirmed the unique mono-naphthoate crystalline form of formula (I), which is referred to as Form B. This unique crystalline form was also observed in IPA after equilibration at room temperature and storage at 60°C for 7 days ( Fig.86 ). After Form A was slurried in water at room temperature overnight, a unique solid form was observed by XRPD. 1 H-NMR confirmed that this substance was a mono-naphthoate crystal and was named Form C ( Fig.86 ). Further characterization of this crystalline form is described below.
[0301] Form B
[0302] After long-term storage at 60°C, water adsorption and equilibration in IPA at room temperature for 7 days, Form B was obtained. The representative XRPD pattern of Form B is shown in Fig.86 Batch HAL-G-32 (5) 1 H-NMR analysis showed an acid:API ratio of 1.0:1, confirming the formation of the mononaphthoate salt of formula (I). Further examination of the hydrogen spectrum showed 3.3 wt% residual THF and 1.2 wt% IPA ( Fig.87 ). TGA analysis provided a thermogram similar to Form A, showing a broad weight loss transition (2.9 wt%) at 80-190 °C, which was attributed to the loss of residual THF and / or IPA, followed by a step transition corresponding to a 0.9 wt% loss ( Fig.88 ). Further DSC analysis showed the same transformation observed in Form A, including a minor exotherm at 191 °C followed by a melting endotherm at 219 °C ( Figure 89(a) ,89(b) Further studies are needed to determine whether the DSC exotherm and the corresponding TGA step transition are due to solid-state transformation or desolvation. The results obtained by characterizing Form B are summarized in Table 7.
[0303] Crystalline Form C
[0304] Form C is obtained by slurrying Form A in water at room temperature overnight ( Fig.86 ). Batch HAL-G-31(6) 1 H-NMR analysis showed an acid:API ratio of 1.0:1, confirming the formation of the mononaphthoate salt of formula (I). 1 Further inspection of the H-NMR spectrum showed no residual solvent, and by TGA, no weight loss was observed ( Fig.87 ). DSC analysis showed a single endotherm at 218 °C, which was attributed to the melting of C ( Figure 89(a) and 89(b) ). The solubility of Form C in water was determined to be 2.3 mg / mL by HPLC. Further research is needed to better understand the stability relationship between Form A, Form B and Form C of the mono-naphthoate salt of Formula (I).
[0305] (18) Succinic acid
[0306] In the 70 mg scale sample, batches HAL-G-26 (37) and batches HAL-G-29 (1) isolated from THF showed consistent crystalline XRPD patterns, which were consistent with the free form pattern of formula (I) ( Fig.91 The inspection of batch HAL-G-26 (37) under cross-polarized light showed needle-shaped birefringent particles ( Fig.92 ). 1H-NMR analysis of batch HAL-G-26 (37) confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.1:1, indicating the formation of a mono-succinate salt of formula (I), which was designated as Form A ( Fig.93 DSC thermoanalysis of the succinate salt showed a single endothermic event at 273 °C, which was attributed to the melting of the crystalline salt ( Fig.94 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A in water was estimated to be ≥140 mg / mL by visual inspection. This salt was selected for comprehensive characterization based on thermal stability, high crystallinity, and improved water solubility compared to the free form.
[0307] The gravimetric moisture absorption test revealed that the succinate form A showed a sharp increase in water absorption at 40% to 50% RH ( Fig.95The salt adsorbed about 2 wt% water, which corresponds to the hemihydrate of the monosuccinate of formula (I). During desorption, a sharp drop in water uptake was observed at 45-35% RH, indicating dehydration. The results show that the hydrate form is unstable below 45% RH. XRPD analysis of the dried sample after water absorption showed that the sample after drying was consistent with that before drying, further confirming that dehydration occurred during the experiment ( Fig.91 After equilibration in IPA at room temperature and storage at 60°C for 7 days, the crystalline form showed no signs of transformation, indicating that Form A is stable ( Fig.91 The above experimental results indicate that Form A is a thermodynamically favorable crystalline form of the mono-succinate of Formula (I). The results obtained by characterizing Form A are summarized in Table 7.
[0308] (19) Glutaric acid
[0309] In a 70 mg scale sample, batch HAL-G-26 (39) isolated from THF provided a crystalline XRPD pattern that was distinct from the diffraction patterns of the free form of formula (I) and all other synthesized salts ( Fig.96 Under cross-polarized light, the solid form was also observed to be crystalline, appearing as birefringent needle-shaped particles ( Fig.97 ). Batch HAL-G-26(36) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed an acid:API ratio of 1.0:1, indicating the formation of a mono-glutarate salt of formula (I), which was designated Form A. 1 Further observation of the H-NMR spectrum showed that about 0.9 wt% THF and 0.1 wt% EtOH ( Fig.98 ). DSC thermal analysis of Form A showed a single endothermic event at 269°C, which was attributed to the melting of the crystalline salt. No weight loss was observed by TGA. Because complete dissolution was observed, the solubility of Form A mono-salt in water was estimated to be in excess of 400 mg / mL by visual inspection. Although the salt showed the desired physical characteristics, it was not selected for further characterization due to the prevalence of counterion deficiency in drug products. The results obtained by characterizing Form A are summarized in Table 7.
[0310] (20) L-pyroglutamic acid
[0311] Crystalline Form A
[0312] In a 70 mg scale sample, batch HAL-G-26 (40) isolated from THF provided a crystalline XRPD pattern that was distinct from that of the free form of formula (I) and all other synthetic salts ( Fig.100This solid form can also be obtained on a 200 mg scale from the same solvent. Optical microscopic analysis confirmed that the solid was crystalline under cross-polarized light, showing needle- and blade-like birefringent particles ( Fig.101 ). Batch HAL-G-26(40) 1 H-NMR analysis confirmed the chemical structure of formula (I) and showed a ratio of acid to API of 1.1:1, indicating the formation of a monoglutamate salt of formula (I), which was named Form A ( Fig.102 ). DSC thermal analysis of Form A showed a single endothermic event at 241 °C, which was attributed to the melting of the crystalline salt ( Fig.99 ). No weight loss was observed by TGA. Since complete dissolution was observed, the solubility of Form A mono-salt in water was estimated to be in excess of 400 mg / mL by visual inspection. Based on the high degree of crystallinity observed by microscopy and XRPD, and the improved water solubility compared to the free form, this salt was selected for comprehensive characterization.
[0313] After equilibration at room temperature and storage at 60°C for 7 days in IPA, Form A showed no signs of crystal transformation, indicating that Form A is stable ( Fig.100 ). These findings indicate that Form A is the thermodynamically favorable crystalline form of the mono-glutamate salt of Formula (I).
[0314] Prior to exposure to relative humidity conditions greater than 80% RH, glutamate Form A was not hygroscopic ( Figure 2 ). At 80% RH to 90% RH, a sharp increase in water adsorption was observed, resulting in deliquescence of the salt. Upon desorption, the salt may form a monohydrate (theoretical value = 4.0 wt%), which was observed to be stable down to 0% RH. The XRPD pattern of the dried solid after moisture absorption is similar to that of Form A ( Fig.100 ) and the Raman spectrum also showed a difference from Form A ( Figure 3 ). H-NMR analysis subsequently confirmed that the dried solid after moisture absorption was a monoglutamic acid crystalline form, named Form B ( Fig.102 ).
[0315] Form B
[0316] As mentioned above, after the crystal form A absorbs moisture, it is dried to obtain the crystal form B. In order to obtain more crystal form B for further characterization, the following simplified moisture absorption experiment was conducted in this experiment: about 30 mg of the monoglutamate crystal form A [batch HAL-G-29 (2)] was stored in a dry open small glass container containing a saturated aqueous solution of Na2HPO4·12H2O to achieve a relative humidity of 95%.
[0317] After equilibration at 95% RH for 5 hours, the solid deliquesced. After the sample was exposed to the laboratory environment (~20% RH) overnight, a dry solid adhered to the sample container was obtained. XRPD analysis of the solid showed a crystalline XRPD pattern similar to Form B ( Fig.100 TGA analysis of Form B showed a 3.3 wt% loss at 40-120 °C, which is comparable to the theoretical water content of mono-glutamate monohydrate (4.0 wt%) ( Figure 4 The DSC spectrum of Form B shows two endothermic transitions at 95°C and 238°C, which are attributed to dehydration and melting, respectively ( Figure 5 ). The results obtained from the characterization of glutamic acid of formula (I) indicate the presence of a crystalline anhydrate (Form A) and a potential monohydrate (Form B). The results obtained from the characterization of Form B are summarized in Table 7.
[0318] Table 7: Characterization results of the crystal forms of each salt form of formula (I)
[0319]
[0320] *Semi-crystalline XRPD spectrum
[0321] D precipitates upon cooling, and the rest precipitates upon the addition of counter ions.
[0322] Table 7 (continued): Characterization results of the crystal forms of each salt form of formula (I)
[0323]
[0324] Other reflections at °2θ = 6.5°
[0325] The above results show that the present invention prepares various salts of formula (I) in different crystal forms. Compared with formula (I), methanesulfonate, phosphate, hydrochloride, succinate, 1-hydroxy-2-naphthoate and L-pyroglutamate have better properties, better crystallinity, solubility or stability. Among the various crystal forms, crystal form A has better properties. Among the above various salts, hydrochloride has higher water solubility, better stability and less hygroscopicity, and has the best comprehensive performance.
[0326] In summary, the present invention provides various salts of the compound of formula (I), as well as their crystal forms and preparation methods. The inventors of the present invention have conducted various studies under the above circumstances. As a result, they found that the hydrochloride of formula (I) has at least one or more of the following characteristics: (1) it shows excellent stability; (2) it shows excellent crystallinity, (3) it shows high water solubility, (4) it does not show deliquescent properties, (5) it shows excellent fluidity, (6) it shows excellent tableting properties, (7) it has a small environmental load during manufacture, (8) it shows less hygroscopicity, and (9) it can be produced on a large scale. Therefore, compared with the free base shown in formula (I), it can be used as a raw material for medicine, and the inventors have completed the present invention.
[0327] Although the present invention has been described in detail, it will be appreciated by those skilled in the art that many changes and modifications may be made. Therefore, the present invention should not be construed as being limited to the specifically described embodiments, and the scope and concept of the present invention will be more easily understood by reference to the appended claims.
Claims
1. A salt of a compound represented by formula (I), characterized in that: The salt is a phosphate, and the X-ray diffraction pattern of the crystal form of the salt has the following peaks of relative intensity at the 2θ diffraction angle shown in Table A-3 below: Table A-3 2. The salt according to claim 1, characterized in that: The X-ray diffraction pattern of the crystalline form of the salt is shown in Figure 48a or Figure 48b.
3. A salt of the compound represented by formula (I), characterized in that: The salt is a hydrochloride salt, and the X-ray diffraction pattern of the crystal form of the salt has the following peaks of relative intensity at the 2θ diffraction angle shown in Table A-4 below: Table A-4 4. The salt according to claim 3, characterized in that: The X-ray diffraction pattern of the crystalline form of the salt is shown in Figure 76a, Figure 76b, Figure 76c or Figure 76d.
5. A salt of the compound represented by formula (I), characterized in that: The salt is L-pyroglutamate, and the X-ray diffraction pattern of the crystal form of the salt has the following peaks of relative intensity at the 2θ diffraction angle shown in Table A-7 below: Table A-7 6. The salt according to claim 5, characterized in that: The X-ray diffraction pattern of the crystalline form of the salt is shown in Figure 100a or Figure 100b.
7. A pharmaceutical preparation, characterized in that: It comprises the salt according to any one of claims 1 to 6, and a pharmaceutically acceptable excipient.
8. Use of the salt according to any one of claims 1 to 6 in the preparation of a medicament for treating a disease, wherein the disease is irritable bowel syndrome, panic disorder, Parkinson's disease, bulimia, obesity, migraine, obsessive-compulsive disorder, Huntington's disease, schizophrenia, epilepsy, Alzheimer's disease, alcohol dependence or alcohol addiction.
